|   |
|---|
|   |  |
| x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

|   |
|---|
|   |  |
| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

|                                                                      |
|----------------------------------------------------------------------|
|                                                                      |  |
| DELAWARE                                                             | 22-2343568 |
| (State or other jurisdiction of                                      | (I.R.S. Employer |
| incorporation or organization)                                       | Identification No.) |
|                                                                 |   |
| 106 ALLEN ROAD, FOURTH FLOOR               BASKING RIDGE, NEW JERSEY | 07920 |
| (Address of principal executive offices)                             | (zip code) |

|                                          |
|------------------------------------------|
|                                          |  |  |
|                                     |   |   |
| Title of Each Class                      |   | Name of Each Exchange On Which Registered |
| Common Stock, par value $0.001 per share |   | The NASDAQ Capital Market |

----

----

|                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------|
|                                                                                                                     |  |
| Large accelerated filer      o                                                        | Accelerated filer     x |
| Non-accelerated filer   o     (Do not check if a smaller reporting company) | Smaller reporting company     o |

----

|                           |
|---------------------------|
|                           |  |  |
| Name                      | Age | Director Since |
| Richard Berman            | 73 | 2006 |
| Steven S. Myers           | 69 | 2006 |
| Eric H.C. Wei             | 59 | 2009 |
| Andrew Pecora, M.D., FACP | 58 | 2011 |
| Steven M. Klosk           | 59 | 2014 |
| Peter Traber              | 61 | 2015 |
| David J. Mazzo, PhD       | 59 | 2015 |
| Robert A. Preti, PhD (1)  | 59 | 2015 |

|                          |
|--------------------------|
|                          |  |  |
| Name                     | Age | Position |
| David J. Mazzo, PhD      | 59 | Chief Executive Officer |
| Robert A. Preti, PhD (1) | 59 | Senior Vice President, Manufacturing and Technical Operations, Chief Technology Officer |
| Joseph Talamo (2)        | 47 | Senior Vice President and Chief Financial Officer |
| Douglas Losordo, MD      | 58 | Senior Vice President, Clinical, Medical and Regulatory, Chief Medical Officer |

----

----

----

----

----

|         |                                                                                                                                                                                                                                             |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | The Board’s review and approval of our business plans and budget (prepared and presented to the Board by the Chief Executive Officer and other management), including the projected opportunities and challenges facing our business; |

|         |                                                                                                             |
|---------|-------------------------------------------------------------------------------------------------------------|
| • | At least quarterly review of our business developments, business plan implementation and financial results; |

|         |                                                                                                                                                                                                                                                     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Our Audit Committee’s oversight of our internal control over financial reporting and its discussions with management and the independent accountants regarding the quality and adequacy of our internal controls and financial reporting; and |

|         |                                                                                                                                                                     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Our Compensation Committee’s review and recommendations to the Board regarding our executive officer compensation and its relationship to our business plans. |

----

|         |                                                                                                                                                  |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| • | serving as an independent and objective party to monitor our financial reporting process, internal control system and disclosure control system; |

|         |                                                                            |
|---------|----------------------------------------------------------------------------|
| • | reviewing and appraising the audit efforts of our independent accountants; |

|         |                                                                                                                                                                                                                                                        |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | assuming direct responsibility for the appointment, compensation, retention and oversight of the work of the outside auditors and for the resolution of disputes between the outside auditors and our management regarding financial reporting issues; |

|         |                                                                                                                                 |
|---------|---------------------------------------------------------------------------------------------------------------------------------|
| • | providing an open avenue of communication among the independent accountants, financial and senior management and the Board; and |

|         |                                                         |
|---------|---------------------------------------------------------|
| • | reviewing and approving all related party transactions. |

----

|         |                                                                                                                                                                                                                                                                   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | evaluate the performance of the Chief Executive Officer in light of our goals and objectives and determine the Chief Executive Officer’s compensation based on this evaluation and such other factors as the Compensation Committee shall deem appropriate; |

|         |                                                           |
|---------|-----------------------------------------------------------|
| • | determine and approve all executive officer compensation; |

|         |                                                                                                                                                                       |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | approve the aggregate amounts and methodology for determination of all salary, bonus, and long-term incentive awards for all employees other than executive officers; |

|         |                                                                                                                      |
|---------|----------------------------------------------------------------------------------------------------------------------|
| • | review and recommend equity-based compensation plans to the full Board and approve all grants and awards thereunder; |

|         |                                                                                                                                                                                                                                                           |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | review and approve changes to our equity-based compensation plans other than those changes that require stockholder approval under the plans, the requirements of NASDAQ or any exchange on which our securities may be listed and/or any applicable law; |

|         |                                                                                                                                                                                                                                                      |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | review and recommend to the full Board changes to our equity-based compensation plans that require stockholder approval under the plans, the requirements of NASDAQ or any exchange on which our securities may be listed and/or any applicable law; |

|         |                                                                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | review and approve changes in our retirement, health, welfare and other benefit programs that result in a material change in costs or the benefit levels provided; |

|         |                                                     |
|---------|-----------------------------------------------------|
| • | administer our equity-based compensation plans; and |

|         |                                                                                                                                                  |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| • | approve, as required by applicable law, the annual Compensation Committee report on executive compensation for inclusion in our proxy statement. |

----

|         |                                                                                                 |
|---------|-------------------------------------------------------------------------------------------------|
| • | should possess the highest personal and professional standards of integrity and ethical values; |

|         |                                                                                                     |
|---------|-----------------------------------------------------------------------------------------------------|
| • | must be committed to promoting and enhancing the long term value of Caladrius for our stockholders; |

|         |                                                                                                                                                                                                                                         |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | should not have any interests that would materially impair his or her ability to (i) exercise independent judgment or (ii) otherwise discharge the fiduciary duties owed as a director to our Caladrius and our stockholders; |

|         |                                                                                                                                                                     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | must be able to represent fairly and equally all of our stockholders without favoring or advancing any particular stockholder or other constituency of the Company; |

|         |                                                                                                                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | must have demonstrated achievement in one of more fields of business, professional, governmental, community, scientific or educational endeavor, and possess mature and objective business judgment and expertise; |

|         |                                                                                                                                  |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| • | must have a general appreciation regarding major issues facing public companies of a size and operational scope similar to ours; |

|         |                                                                        |
|---------|------------------------------------------------------------------------|
| • | must have adequate time to devote to the Board and its committees; and |

|         |                                                                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | is expected to have sound judgment, derived from management or policy-making experience that demonstrates an ability to function effectively in an oversight role. |

----

----

----

|         |                                                         |
|---------|---------------------------------------------------------|
| • | attract and retain talented and experienced executives; |

|         |                                                                                                             |
|---------|-------------------------------------------------------------------------------------------------------------|
| • | motivate, reward and retain executives whose knowledge, skills and performance are critical to our success; |

|         |                                                                                                                           |
|---------|---------------------------------------------------------------------------------------------------------------------------|
| • | ensure fairness among the executive management team by recognizing the contributions each executive makes to our success; |

|         |                                                                                   |
|---------|-----------------------------------------------------------------------------------|
| • | focus executive behavior on achievement of our corporate objectives and strategy; |

|         |                                                                                                                     |
|---------|---------------------------------------------------------------------------------------------------------------------|
| • | build a culture of “pay for performance”, while not rewarding unnecessary or excessive risk taking; and |

|         |                                                                                                                                  |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| • | align the interests of management and stockholders by providing management with longer-term incentives through equity ownership. |

----

|                                                |
|------------------------------------------------|
|                                                |  |
| Caladrius' Peer Group for 2014                 |
| Advanced Cell Technology  (Ocata Therapeutics) | Lion Biotechnologies |
| Amicus Therapeutics                            | Mimedx Inc Com |
| Argos Therapeutics                             | Momenta Pharmaceuticals |
| Athersys                                       | NeuralStem |
| BioTime                                        | Northwest Biotherapeutics |
| Cumberland Pharmaceuticals                     | Opexa Therapeutic |
| Cytomedix (Nuo Therapeutics)                   | Organovo Holdings |
| Cytori Therapeutics                            | Osiris Therapeutics |
| DURECT Corporation                             | Pluristem Therapeutics |
| Fibrocell Science                              | Progenics Pharmaceutical |
| Geron Corporation                              | Sangamo Biosciences |
| Immunocellular Therapeutics                    | Stemcells |

----

----

|                 |
|-----------------|
|                 |  |
|            | Option Award |
| Robin Smith     | 150,000 |
| Robert Preti    | 50,000 |
| Douglas Losordo | 40,000 |
| Joseph Talamo   | 30,000 |
| Andrew Pecora   | 75,000 |

|                 |
|-----------------|
|                 |  |  |
|            | Stock Award | Option Award |
| Robin Smith     | 40,000 | — |
| David Mazzo     | 80,000 | — |
| Robert Vaters   | 60,000 | — |
| Robert Preti    | — | 33,750 |
| Douglas Losordo | — | 33,750 |
| Joseph Talamo   | 22,500 | — |
| Andrew Pecora   | 10,000 | — |

----

----

----

|                                                                                   |
|-----------------------------------------------------------------------------------|
|                                                                                   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Name andPrincipal Function                                                        | Year | Salary |    | Bonus |    | StockAwards(1) |   | OptionAwards(1) |   | All OtherCompensation |    | TotalCompensation |
| David J. Mazzo,  Chief Executive Officer (2)                            | 2015 | $ | 541,371 |  |   | $ | — |  |   | $ | 736,010 |  |   | $ | 883,057 |  |   | $ | 665,096 |  | (3)  | $ | 2,825,534 |  |
| 2014                                                                              | $ | — |  |   | $ | — |  |   | $ | — |  |   | $ | — |  |   | $ | — |  |   | $ | — |  |
| 2013                                                                              | $ | — |  |   | $ | — |  |   | $ | — |  |   | $ | — |  |   | $ | — |  |   | $ | — |  |
| Robin Smith,  Former Chief Executive Officer (4)                                  | 2015 | $ | 237,405 |  |   | $ | 243,120 |  |   | $ | 156,773 |  |   | $ | 950,770 |  |   | $ | 1,264,922 |  | (5)  | $ | 2,852,990 |  |
| 2014                                                                              | $ | 545,000 |  |   | $ | 392,400 |  |   | $ | 730,380 |  |   | $ | 1,093,257 |  |   | $ | 559,739 |  | (6)  | $ | 3,320,776 |  |
| 2013                                                                              | $ | 495,000 |  |   | $ | 450,000 |  |   | $ | — |  |   | $ | 249,685 |  |   | $ | 40,782 |  |   | $ | 1,235,467 |  |
| Joseph Talamo,  Chief Financial Officer (7)                             | 2015 | $ | 261,932 |  |   | $ | — |  |   | $ | 50,850 |  |   | $ | 72,438 |  |   | $ | 46,522 |  | (8)  | $ | 431,742 |  |
| 2014                                                                              | $ | 227,700 |  |   | $ | 42,695 |  |   | $ | 39,142 |  |   | $ | 287,447 |  |   | $ | 22,845 |  | (9)  | $ | 619,828 |  |
| 2013                                                                              | $ | 219,583 |  |   | $ | 100,000 |  |   | $ | — |  |   | $ | 107,418 |  |   | $ | — |  |   | $ | 427,001 |  |
| Robert Vaters,  Former President and Chief       Financial Officer (10) | 2015 | $ | 320,360 |  |   | $ | — |  |   | $ | 397,870 |  |   | $ | 883,057 |  |   | $ | 837,162 |  | (11)  | $ | 2,438,450 |  |
| 2014                                                                              | $ | — |  |   | $ | — |  |   | $ | — |  |   | $ | — |  |   | $ | — |  |   | $ | — |  |
| 2013                                                                              | $ | — |  |   | $ | — |  |   | $ | — |  |   | $ | — |  |   | $ | — |  |   | $ | — |  |
| Robert Dickey IV, Former Chief Financial Officer (12)                             | 2015 | $ | 2,348 |  |   | $ | — |  |   | $ | — |  |   | $ | — |  |   | $ | 226,927 |  | (13)  | $ | 229,275 |  |
| 2014                                                                              | $ | 310,000 |  |   | $ | 23,250 |  |   | $ | 39,142 |  |   | $ | 287,447 |  |   | $ | 60,705 |  | (14)  | $ | 720,544 |  |
| 2013                                                                              | $ | 150,626 |  |   | $ | 40,000 |  |   | $ | — |  |   | $ | 229,462 |  |   | $ | 15,283 |  |   | $ | 435,371 |  |
| Robert Preti,  President and Chief Scientific   Officer of PCT          | 2015 | $ | 410,000 |  |   | $ | — |  |   | $ | — |  |   | $ | 316,652 |  |   | $ | 4,911 |  | (15)  | $ | 731,563 |  |
| 2014                                                                              | $ | 364,000 |  |   | $ | 54,600 |  |   | $ | 39,539 |  |   | $ | 599,701 |  |   | $ | 22,570 |  | (16)  | $ | 1,080,410 |  |
| 2013                                                                              | $ | 349,231 |  |   | $ | 145,000 |  |   | $ | — |  |   | $ | 143,224 |  |   | $ | — |  |   | $ | 637,455 |  |
| Douglas Losordo,  Chief Medical Officer                                 | 2015 | $ | 405,000 |  |   | $ | — |  |   | $ | 15,900 |  |   | $ | 145,483 |  |   | $ | 17,826 |  | (17)  | $ | 584,209 |  |
| 2014                                                                              | $ | 385,000 |  |   | $ | 60,150 |  |   | $ | 101,542 |  |   | $ | 365,671 |  |   | $ | 60,293 |  | (18)  | $ | 972,656 |  |
| 2013                                                                              | $ | 291,500 |  |   | $ | 40,000 |  |   | $ | 145,800 |  |   | $ | 343,070 |  |   | $ | 30,846 |  |   | $ | 851,216 |  |
| Andrew Pecora,   Former Chief Visionary Officer                         | 2015 | $ | 162,462 |  | (19)  | $ | — |  |   | $ | 22,600 |  |   | $ | 181,095 |  |   | $ | 23,457 |  | (20)  | $ | 389,613 |  |
| 2014                                                                              | $ | 240,000 |  | (21)  | $ | — |  |   | $ | 310,502 |  |   | $ | 543,983 |  |   | $ | 322,272 |  | (22)  | $ | 1,416,757 |  |
| 2013                                                                              | $ | 221,538 |  | (23)  | $ | 365,004 |  | (24)  | $ | — |  |   | $ | 286,456 |  |   | $ | — |  |   | $ | 872,998 |  |

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (1) | Amounts shown under “Stock Awards” and “Option Awards” represent the aggregate grant date fair value computed in accordance with FASB ASC Topic 718, in accordance with SEC rules. See Note 13 to the Notes to the Consolidated Financial Statements in the 2015 Annual Report, for a discussion of assumptions made in such valuations. All stock awards, option awards and other shares discussed in this table were issued under the Company's Amended and Restated 2009 Equity Compensation Plan (the "2009 Plan"), with a per share price generally equal to the fair market value of a share of our common stock on the date of grant. |

|     |                                                                                                             |
|-----|-------------------------------------------------------------------------------------------------------------|
| (2) | Effective January 5, 2015, Dr. Mazzo was appointed to serve as Chief Executive Officer of the Company. |

|     |                                                                                                                                              |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------|
| (3) | Consisted of (i) a tax gross up $641,915 on stock awards, (ii) a car allowance of $12,000, and (iii) $4,178 of Company 401(k) match. |

|     |                                                                                                                                                                                                                                                                                                                                                            |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | Effective January 5, 2015, Dr. Smith resigned from her position as CEO and was appointed Executive Chair of the Board. Effective June 5, 2015, Dr. Smith resigned from her position as Executive Chair of the Board while continuing to serve as chairperson of the Board.  Effective December 18, 2015, Dr. Smith resigned from the Board. |

|     |                                                                                                                               |
|-----|-------------------------------------------------------------------------------------------------------------------------------|
| (5) | Consisted of (i) severance payments of $1,020,000, (ii) a tax gross up $183,846 on stock awards, (iii) a car allowance of |

----

|     |                                                                                                                                                                                                                                                    |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (6) | Consisted of (i) a tax gross up $511,271 on stock awards, (ii) a car allowance of $12,000, (iii) approximately $21,652 paid by us on behalf of Dr. Smith for life and disability insurance; and (iv) $14,816 for club membership dues. |

|     |                                                                                                              |
|-----|--------------------------------------------------------------------------------------------------------------|
| (7) | Effective October 5, 2015, Mr. Talamo was appointed to serve as Chief Financial Officer of the Company. |

|     |                                                                                                           |
|-----|-----------------------------------------------------------------------------------------------------------|
| (8) | Consisted of (i) a tax gross up $45,039 on stock awards, and (ii) $1,483 of Company 401(k) match. |

|     |                                                          |
|-----|----------------------------------------------------------|
| (9) | Consisted of a tax gross up $22,845 on stock awards. |

|      |                                                                                                                                                                                                                                                                                     |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (10) | Effective January 5, 2015, Mr. Vaters was appointed to serve as President and Chief Financial Officer of the Company.  Effective October 5, 2015, Mr. Vaters was no longer serving as President and Chief Financial Officer and was no longer an employee of the Company. |

|      |                                                                                                                                                                                                                 |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (11) | Consisted of (i) severance payments of $425,000, (ii) a tax gross up $385,914 on stock awards, (iii) a car allowance of $9,000, (iv) $3,465 legal fee reimbursement, and (v) COBRA payments of $13,784. |

|      |                                                                                                                                      |
|------|--------------------------------------------------------------------------------------------------------------------------------------|
| (12) | Effective January 5, 2015, Mr. Dickey was no longer serving as Chief Financial Officer and was no longer an employee of the Company. |

|      |                                                                                                                                                    |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| (13) | Consists of (i) severance of $180,833 on stock awards, (ii) COBRA payments of $35,933, and (iii) relocation related reimbursements of $10,160. |

|      |                                                                                                                       |
|------|-----------------------------------------------------------------------------------------------------------------------|
| (14) | Consists of (i) a tax gross up of $27,448 on stock awards, and (ii) relocation related reimbursements of $33,257. |

|      |                                                  |
|------|--------------------------------------------------|
| (15) | Consisted of $4,911 of Company 401(k) match. |

|      |                                                          |
|------|----------------------------------------------------------|
| (16) | Consisted of a tax gross up $22,570 on stock awards. |

|      |                                                         |
|------|---------------------------------------------------------|
| (17) | Consisted of a tax gross up $9,326 on stock awards. |

|      |                                                                                                                                        |
|------|----------------------------------------------------------------------------------------------------------------------------------------|
| (18) | Consisted of (i) a tax gross up $59,558 on stock awards, and (ii) $735 paid by us on behalf of Dr. Losordo for life insurance. |

|      |                                                                                                                                                                                                                                                                                                                               |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (19) | Pursuant to an arrangement approved by the Compensation Committee, Dr. Pecora elected to receive an aggregate of $63,894 of this amount in shares of our common stock issued under the 2009 Plan and in lieu of cash.  For more information on these grants of our common stock, see "Grants of Plan-Based Awards" below. |

|      |                                                          |
|------|----------------------------------------------------------|
| (20) | Consisted of a tax gross up $23,457 on stock awards. |

|      |                                                                                                                                                                                                                                                                                                                           |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (21) | Pursuant to an arrangement approved by the Compensation Committee, Dr. Pecora elected to receive an aggregate of $80,598 of this amount in shares of our common stock issued under the 2009 Plan and in lieu of cash.  For more information on these grants of our common stock, see "Grants of Plan-Based Awards" below. |

|      |                                                           |
|------|-----------------------------------------------------------|
| (22) | Consisted of a tax gross up $322,272 on stock awards. |

|      |                                                                                                                                                                                                                       |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (23) | Pursuant to an arrangement approved by the Compensation Committee, Dr. Pecora elected to receive an aggregate of $80,245 of this amount in shares of our common stock issued under the 2009 Plan and in lieu of cash. |

|      |                                                                                                                    |
|------|--------------------------------------------------------------------------------------------------------------------|
| (24) | Dr. Pecora's 2013 bonus was paid in stock.  He received a stock award of 46,976 shares issued under the 2009 Plan. |

----

----

----

----

----

----

----

----

----

|                                                              |
|--------------------------------------------------------------|
|                                                              |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                         |   |   |   | Before Change in Control Termination w/o Cause or for Good Reason |   | After Change in Control Termination w/o Cause or for Good Reason |   | Voluntary Termination |   |
| Name                                                         |   | Benefit |   | ($) |   | ($) |   | ($) |   |
| David J. Mazzo                                               |   | Severance |   | 817,500 |  |   | 817,500 |  |   | 817,500 |  |   |
|   Chief Executive Officer (1)                      |   | Health Benefits |   | 21,600 |  |   | 21,600 |  |   | 21,600 |  |   |
|                                                         |   | Equity Award Acceleration |   |   |   |   |   |   |   |
|                                                         |   | Total |   | 839,100 |  |   | 839,100 |  |   | 839,100 |  |   |
| Robin Smith                                                  |   | Severance |   | 480,525 |  |   | 480,525 |  |   | 480,525 |  |   |
|   Former Chief Executive Officer (2)               |   | Health Benefits |   | 21,600 |  |   | 21,600 |  |   | 21,600 |  |   |
|                                                         |   | Equity Award Acceleration |   | — |  |   | — |  |   | — |  |   |
|                                                         |   | Total |   | 502,125 |  |   | 502,125 |  |   | 502,125 |  |   |
| Joseph Talamo                                                |   | Severance |   | 150,000 |  |   | 150,000 |  |   | 150,000 |  |   |
|   Chief Financial Officer (3)                      |   | Health Benefits |   | 10,800 |  |   | 10,800 |  |   | 10,800 |  |   |
|                                                         |   | Equity Award Acceleration |   | — |  |   | — |  |   | — |  |   |
|                                                         |   | Total |   | 160,800 |  |   | 160,800 |  |   | 160,800 |  |   |
| Robert S. Vaters                                             |   | Severance |   | 323,580 |  |   | 323,580 |  |   | 323,580 |  |   |
|   Former President and Chief Financial Officer (4) |   | Health Benefits |   | 10,800 |  |   | 10,800 |  |   | 10,800 |  |   |
|                                                         |   | Equity Award Acceleration |   | — |  |   | — |  |   | — |  |   |
|                                                         |   | Total |   | 334,380 |  |   | 334,380 |  |   | 334,380 |  |   |
| Robert Dickey IV                                             |   | Severance |   | — |  |   | — |  |   | — |  |   |
|   Former Chief Financial Officer (5)               |   | Health Benefits |   | 10,800 |  |   | 10,800 |  |   | 10,800 |  |   |
|                                                         |   | Equity Award Acceleration |   | — |  |   | — |  |   | — |  |   |
|                                                         |   | Total |   | 10,800 |  |   | 10,800 |  |   | 10,800 |  |   |
| Robert Preti                                                 |   | Severance |   | 364,000 |  |   | 364,000 |  |   | 364,000 |  |   |
|   President and Chief                              |   | Health Benefits |   | 21,600 |  |   | 21,600 |  |   | 21,600 |  |   |
|   Scientific Officer of PCT                        |   | Equity Award Acceleration |   | — |  |   | — |  |   | — |  |   |
|                                                         |   | Total |   | 385600 |  |   | 385,600 |  |   | 385,600 |  |   |
| Douglas Losordo                                              |   | Severance |   | 32,083 |  |   | 32,083 |  |   | 32,083 |  |   |
|   Chief Medical Officer                            |   | Health Benefits |   | 10,800 |  |   | 10,800 |  |   | 10,800 |  |   |
|                                                         |   | Equity Award Acceleration |   | — |  |   | 37,700 |  |   | — |  |   |
|                                                         |   | Total |   | 42,883 |  |   | 80,583 |  |   | 42,883 |  |   |
| Andrew Pecora                                                |   | Severance |   | 60,000 |  |   | 60,000 |  |   | 60,000 |  |   |
|   Chief Visionary Officer                          |   | Health Benefits |   | — |  |   | — |  |   | — |  |   |
|                                                         |   | Equity Award Acceleration |   | — |  |   | — |  |   | — |  |   |
|                                                         |   | Total |   | 60,000 |  |   | 60,000 |  |   | 60,000 |  |   |

|     |                                                                                                             |
|-----|-------------------------------------------------------------------------------------------------------------|
| (1) | Effective January 5, 2015, Dr. Mazzo was appointed to serve as Chief Executive Officer of the Company. |

|     |                                                                                                                                                                                                                                                                                                                                                            |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Effective January 5, 2015, Dr. Smith resigned from her position as CEO and was appointed Executive Chair of the Board. Effective June 5, 2015, Dr. Smith resigned from her position as Executive Chair of the Board while continuing to serve as chairperson of the Board.  Effective December 18, 2015, Dr. Smith resigned from the Board. |

|     |                                                                                                              |
|-----|--------------------------------------------------------------------------------------------------------------|
| (3) | Effective October 5, 2015, Mr. Talamo was appointed to serve as Chief Financial Officer of the Company. |

|     |                                                                                                                                                                                                                                                                                     |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | Effective January 5, 2015, Mr. Vaters was appointed to serve as President and Chief Financial Officer of the Company.  Effective October 5, 2015, Mr. Vaters was no longer serving as President and Chief Financial Officer and was no longer an employee of the Company. |

|     |                                                                                                                                      |
|-----|--------------------------------------------------------------------------------------------------------------------------------------|
| (5) | Effective January 5, 2015, Mr. Dickey was no longer serving as Chief Financial Officer and was no longer an employee of the Company. |

----

|                                                      |
|------------------------------------------------------|
|                                                      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Named Officer                                        | Grant Date | Estimated Future Payouts Under Equity Incentive Plan Awards and Non-Equity Incentive Plan Awards | All Other Stock Awards: Number of Shares of Stock or Units |   | All Other Option Awards: Number of Securities Underlying Options | Exercise or Base Price of Option Awards | Market Price on Date of Grant |  Full Grant Date Fair Value of Stock and Option Awards |
|                                                 |   | Threshold | Target | Maximum |   |   |   |   |   |   |
|                                                 |   | ($) | ($) | ($) | (#) |   | (#) | ($/Sh) | ($/Sh) |  ($) (1) |
| Robin Smith                                          | 1/16/2015 | — |  | — |  | — |  | 19,159 |  |   | — |  | $ | — |  | $ | 3.48 |  | $ | 66,673 |  |
|    Former Chief Executive Officer (2) | 6/2/2015 | — |  | — |  | — |  | 40,000 |  |   | — |  | $ | — |  | $ | 2.25 |  | $ | 90,100 |  |
|                                                 | 1/2/2015 | — |  | — |  | — |  | — |  |   | 250,000 |  | $ | 3.73 |  | $ | — |  | $ | 588,580 |  |
|                                                 | 1/2/2015 | — |  | — |  | — |  | — |  |   | 150,000 |  | $ | 3.73 |  | $ | — |  | $ | 362,190 |  |
| David J. Mazzo (3)                                   | 1/16/2015 | — |  | — |  | — |  | 159,543 |  |   | — |  | $ | — |  | $ | 3.48 |  | $ | 555,210 |  |
|    Chief Executive Officer            | 6/2/2015 | — |  | — |  | — |  | 80,000 |  |   | — |  | $ | — |  | $ | 2.26 |  | $ | 180,800 |  |
|                                                 | 1/5/2015 | — |  | — |  | — |  | — |  |   | 400,000 |  | $ | 3.50 |  | $ | — |  | $ | 883,057 |  |
| Robert S. Vaters (4)                                 | 1/16/2015 | — |  | — |  | — |  | 75,365 |  |   | — |  | $ | — |  | $ | 3.48 |  | $ | 262,270 |  |
|    Former President and               | 6/2/2015 | — |  | — |  | — |  | 60,000 |  |   | — |  | $ | — |  | $ | 2.26 |  | $ | 135,600 |  |
|    Chief Financial Officer            | 1/5/2015 | — |  | — |  | — |  | — |  |   | 400,000 |  | $ | 3.50 |  | $ | — |  | $ | 883,057 |  |
| Robert Preti                                         | 12/22/2015 | — |  | — |  | — |  | — |  |   | 200,000 |  | $ | 1.12 |  | $ | — |  | $ | 147,024 |  |
|    President and Chief Scientific     | 6/2/2015 | — |  | — |  | — |  | — |  |   | 33,750 |  | $ | 2.26 |  | $ | — |  | $ | 48,899 |  |
|    Officer of PCT                     | 1/2/2015 | — |  | — |  | — |  | — |  |   | 50,000 |  | $ | 3.73 |  | $ | — |  | $ | 120,730 |  |
| Douglas Losordo                                      | 8/5/2015 | — |  | — |  | — |  | 10,000 |  | (5) | — |  | $ | — |  | $ | 1.59 |  | $ | 15,900 |  |
|    Chief Medical Officer              | 6/2/2015 | — |  | — |  | — |  | — |  |   | 33,750 |  | $ | 2.26 |  | $ | — |  | $ | 48,899 |  |
|                                                 | 1/2/2015 | — |  | — |  | — |  | — |  |   | 40,000 |  | $ | 3.73 |  | $ | — |  | $ | 96,584 |  |
| Joseph Talamo (6)                                    | 6/2/2015 | — |  | — |  | — |  | 22,500 |  |   | — |  | $ | — |  | $ | 2.26 |  | $ | 50,850 |  |
|    Chief Financial Officer            | 1/2/2015 | — |  | — |  | — |  | — |  |   | 30,000 |  | $ | 3.73 |  | $ | — |  | $ | 72,438 |  |
| Andrew Pecora (7)                                    | 1/2/2015 | — |  | — |  | — |  | 1,715 |  |   | — |  | $ | — |  | $ | 3.73 |  | $ | 6,397 |  |
|    Former Chief Visionary Officer     | 1/15/2015 | — |  | — |  | — |  | 684 |  | (7) | — |  | $ | — |  | $ | 3.48 |  | $ | 2,380 |  |
|                                                 | 1/29/2015 | — |  | — |  | — |  | 746 |  | (7) | — |  | $ | — |  | $ | 3.64 |  | $ | 2,715 |  |
|                                                 | 2/12/2015 | — |  | — |  | — |  | 753 |  | (7) | — |  | $ | — |  | $ | 3.64 |  | $ | 2,741 |  |
|                                                 | 2/26/2015 | — |  | — |  | — |  | 672 |  | (7) | — |  | $ | — |  | $ | 3.83 |  | $ | 2,574 |  |
|                                                 | 3/12/2015 | — |  | — |  | — |  | 688 |  | (7) | — |  | $ | — |  | $ | 3.90 |  | $ | 2,683 |  |
|                                                 | 3/26/2015 | — |  | — |  | — |  | 848 |  | (7) | — |  | $ | — |  | $ | 2.77 |  | $ | 2,349 |  |
|                                                 | 4/9/2015 | — |  | — |  | — |  | 899 |  | (7) | — |  | $ | — |  | $ | 2.92 |  | $ | 2,625 |  |
|                                                 | 4/23/2015 | — |  | — |  | — |  | 1,081 |  | (7) | — |  | $ | — |  | $ | 3.05 |  | $ | 3,297 |  |
|                                                 | 5/7/2015 | — |  | — |  | — |  | 1,308 |  | (7) | — |  | $ | — |  | $ | 2.35 |  | $ | 3,074 |  |
|                                                 | 5/19/2015 | — |  | — |  | — |  | 925 |  | (7) | — |  | $ | — |  | $ | 2.34 |  | $ | 2,165 |  |
|                                                 | 5/21/2015 | — |  | — |  | — |  | 1,354 |  | (7) | — |  | $ | — |  | $ | 2.95 |  | $ | 3,993 |  |
|                                                 | 6/2/2015 | — |  | — |  | — |  | 10,000 |  |   | — |  | $ | — |  | $ | 2.26 |  | $ | 22,600 |  |
|                                                 | 6/4/2015 | — |  | — |  | — |  | 1,330 |  | (7) | — |  | $ | — |  | $ | 2.34 |  | $ | 3,113 |  |
|                                                 | 6/18/2015 | — |  | — |  | — |  | 1,597 |  | (7) | — |  | $ | — |  | $ | 1.95 |  | $ | 3,113 |  |
|                                                 | 7/2/2015 | — |  | — |  | — |  | 2,097 |  | (7) | — |  | $ | — |  | $ | 1.85 |  | $ | 3,879 |  |
|                                                 | 7/2/2015 | — |  | — |  | — |  | 227 |  | (7) | — |  | $ | — |  | $ | 1.85 |  | $ | 420 |  |
|                                                 | 7/15/2015 | — |  | — |  | — |  | 2,086 |  | (7) | — |  | $ | — |  | $ | 1.90 |  | $ | 3,963 |  |
|                                                 | 7/30/2015 | — |  | — |  | — |  | 2,277 |  | (7) | — |  | $ | — |  | $ | 1.73 |  | $ | 3,939 |  |
|                                                 | 8/13/2015 | — |  | — |  | — |  | 2,831 |  | (7) | — |  | $ | — |  | $ | 1.50 |  | $ | 4,247 |  |
|                                                 | 8/27/2015 | — |  | — |  | — |  | 3,108 |  | (7) | — |  | $ | — |  | $ | 1.36 |  | $ | 4,227 |  |
|                                                 | 1/2/2015 | — |  | — |  | — |  | — |  |   | 75,000 |  | $ | 3.73 |  | $ | — |  | $ | 181,095 |  |

|     |                                                                                                                                          |
|-----|------------------------------------------------------------------------------------------------------------------------------------------|
| (1) | Computed in accordance with FASB ASC Topic 718. See Note 13 to the Notes to the Consolidated Financial Statements in the 2015 Form 10-K. |

----

|     |                                                                                                                                                                                                                                                                                                                                                                      |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Effective January 5, 2015, Dr. Smith resigned from her position as CEO and was appointed Executive Chair of the Board. Effective June 5, 2015, Dr. Smith resigned from her position as Executive Chair of the Board while continuing to serve as chair person of the Board.  Effective December 18, 2015, Dr. Smith resigned resigned from the Board. |

|     |                                                                                                             |
|-----|-------------------------------------------------------------------------------------------------------------|
| (3) | Effective January 5, 2015, Dr. Mazzo was appointed to serve as Chief Executive Officer of the Company. |

|     |                                                                                                                                                                                                                                                                                     |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | Effective January 5, 2015, Mr. Vaters was appointed to serve as President and Chief Financial Officer of the Company.  Effective October 5, 2015, Mr. Vaters was no longer serving as President and Chief Financial Officer and was no longer an employee of the Company. |

|     |                                                                                                |
|-----|------------------------------------------------------------------------------------------------|
| (5) | Consists of an award granted to Dr. Losordo pursuant to the terms of his employment agreement. |

|     |                                                                                                              |
|-----|--------------------------------------------------------------------------------------------------------------|
| (6) | Effective October 5, 2015, Mr. Talamo was appointed to serve as Chief Financial Officer of the Company. |

|     |                                                                                                                                          |
|-----|------------------------------------------------------------------------------------------------------------------------------------------|
| (7) | Represents shares issued to Dr. Pecora in lieu of cash compensation as reflected in footnote 19 of the Summary Compensation Table above. |

|                  |
|------------------|
|                  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Name             |   | Number of Securities Underlying Unexercised Options (#) Exercisable |    | Number of Securities Underlying Unexercised Options (#) Unexercisable |   | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options |   | Option Exercise Price** |   | Option Expiration Date |
| Robin L. Smith   |   | 1,500 |  | (1)  | — |  |   | — |  |   | $19.00 |   | 12/4/2016 |
|             |   | 5,500 |  | (2)  | — |  |   | — |  |   | $19.00 |   | 1/17/2017 |
|             |   | 25,000 |  | (3)  | — |  |   | — |  |   | $19.00 |   | 9/26/2017 |
|             |   | 12,000 |  | (4)  | — |  |   | — |  |   | $16.30 |   | 2/26/2018 |
|             |   | 500 |  | (5)  | — |  |   | — |  |   | $11.30 |   | 10/30/2018 |
|             |   | 10,000 |  | (6)  | — |  |   | — |  |   | $19.50 |   | 5/20/2019 |
|             |   | 50,000 |  | (7)  | — |  |   | — |  |   | $17.10 |   | 7/7/2019 |
|             |   | 75,000 |  | (8)  | — |  |   | — |  |   | $20.40 |   | 10/28/2019 |
|             |   | 22,968 |  | (9)  | — |  |   | — |  |   | $19.00 |   | 10/29/2016 |
|             |   | 20,000 |  | (10)  | — |  |   | — |  |   | $16.60 |   | 11/3/2019 |
|             |   | 150,000 |  | (11)  | — |  |   | — |  |   | $17.40 |   | 4/3/2021 |
|             |   | 79,000 |  | (12)  | — |  |   | — |  |   | $5.20 |   | 1/3/2022 |
|             |   | 40,263 |  | (13)  | — |  |   | — |  |   | $3.60 |   | 4/25/2022 |
|             |   | 70,000 |  | (14)  | — |  |   | — |  |   | $5.20 |   | 7/4/2022 |
|             |   | 50,000 |  | (15)  | — |  |   | — |  |   | $6.20 |   | 1/1/2023 |
|             |   | 131,000 |  | (16)  | — |  |   | — |  |   | $7.77 |   | 1/1/2024 |
|             |   | 75,000 |  | (17)  | — |  |   | — |  |   | $6.21 |   | 8/1/2024 |
|             |   | 250,000 |  | (18)  | — |  |   | — |  |   | $3.73 |   | 1/2/2025 |
|             |   | 150,000 |  | (19)  | — |  |   | — |  |   | $3.73 |   | 1/2/2025 |
| David J. Mazzo   |   | 175,000 |  | (20)  | 225,000 |  | (20)  | — |  |   | $3.50 |   | 1/5/2025 |
| Robert S. Vaters |   | 400,000 |  | (21)  | — |  |   | — |  |   | $3.50 |   | 1/3/2016 |
| Robert Preti     |   | 40,000 |  | (22)  | — |  |   | — |  |   | $15.00 |   | 1/18/2021 |
|             |   | 27,640 |  | (23)  | — |  |   | — |  |   | $5.20 |   | 1/3/2022 |
|             |   | 5,500 |  | (24)  | — |  |   | — |  |   | $3.60 |   | 4/25/2022 |
|             |   | 30,000 |  | (25)  | — |  |   | — |  |   | $6.20 |   | 1/1/2023 |
|             |   | 62,500 |  | (26)  | 12,500 |  | (26)  | — |  |   | $7.77 |   | 1/1/2024 |
|             |   | 25,000 |  | (27)  | — |  |   | — |  |   | $6.21 |   | 8/1/2024 |
|             |   | 30,000 |  | (28)  | — |  |   | — |  |   | $5.10 |   | 10/27/2024 |

----

|                 |
|-----------------|
|                 |  |  |  |  |  |  |  |  |  |  |  |  |  |
|            |   | 37,500 |  | (29)  | 12,500 |  | (29)  | — |  |   | $3.73 |   | 1/2/2025 |
|            |   | 14,765 |  | (30)  | 18,985 |  | (30)  | — |  |   | $2.26 |   | 6/2/2025 |
|            |   | 62,500 |  | (31)  | 137,500 |  | (31)  | — |  |   | $1.12 |   | 12/22/2025 |
| Douglas Losordo |   | 600 |  | (32)  | — |  |   | — |  |   | $19.00 |   | 10/15/2016 |
|            |   | 40,000 |  | (33)  | 30,000 |  | (33)  | — |  |   | $7.29 |   | 8/4/2023 |
|            |   | 41,666 |  | (34)  | 8,334 |  | (34)  | — |  |   | $7.77 |   | 1/1/2024 |
|            |   | 25,000 |  | (35)  | — |  |   | — |  |   | $6.21 |   | 8/1/2024 |
|            |   | 30,000 |  | (36)  | 10,000 |  | (36)  | — |  |   | $3.73 |   | 1/2/2025 |
|            |   | 14,765 |  | (37)  | 18,985 |  | (37)  | — |  |   | $2.26 |   | 6/2/2025 |
| Joseph Talamo   |   | 32,500 |  | (38)  | — |  |   | — |  |   | $14.30 |   | 6/28/2021 |
|            |   | 7,500 |  | (39)  | — |  |   | — |  |   | $5.20 |   | 1/3/2022 |
|            |   | 22,500 |  | (40)  | — |  |   | — |  |   | $6.20 |   | 1/1/2023 |
|            |   | 35,000 |  | (41)  | — |  |   | — |  |   | $7.77 |   | 1/1/2024 |
|            |   | 25,000 |  | (42)  | — |  |   | — |  |   | $6.21 |   | 8/1/2024 |
|            |   | 22,500 |  | (43)  | 7,500 |  | (43)  | — |  |   | $3.73 |   | 1/2/2025 |
| Andrew Pecora   |   | 40,000 |  | (44)  | — |  |   | — |  |   | $15.00 |   | 1/18/2021 |
|            |   | 50,000 |  | (45)  | — |  |   | — |  |   | $7.10 |   | 8/16/2021 |
|            |   | 17,500 |  | (46)  | — |  |   | — |  |   | $5.20 |   | 1/3/2022 |
|            |   | 14,000 |  | (47)  | — |  |   | — |  |   | $3.60 |   | 4/25/2022 |
|            |   | 30,000 |  | (48)  | — |  |   | — |  |   | $6.20 |   | 1/1/2023 |
|            |   | 24,375 |  | (49)  | 3,125 |  | (49)  | — |  |   | $7.29 |   | 8/4/2023 |
|            |   | 83,333 |  | (50)  | 16,667 |  | (50)  | — |  |   | $7.77 |   | 1/1/2024 |
|            |   | 56,250 |  | (51)  | 18,750 |  | (51)  | — |  |   | $3.73 |   | 1/2/2025 |

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ** | All option awards were made under and are governed by the terms of  the Company’s 2003 Equity Participation Plan or Caladrius' 2009 Amended & Restated Equity Compensation Plan which was approved by our stockholders at our 2014 annual stockholder meeting on October 6, 2014. The 2009 Amended & Restated Plan  increased the aggregate number of shares of the our common stock available for issuance thereunder by 3,000,000 shares, from 5,995,000 shares to 8,995,000 shares. |

|     |                                                                                                                                                                                                                                                                                            |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (1) | Consists of options granted to Dr. Smith by the Compensation Committee on December 5, 2006, which vested as to 1,000 options upon grant and as to 500 options on August 9, 2007 upon our common stock being listed for trading on the American Stock Exchange (now known as the NYSE MKT). |

|     |                                                                                                                                                                                                                                                                                                                                    |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | This option was granted to Dr. Smith in connection with her entering into an amendment to her employment agreement on January 26, 2007, and vested as to (i) 2,500 options upon the first closings in Caladrius' January 2007 private placement, (ii) 1,500 options on June 30, 2007 and (iii) 1,500 options on December 31, 2007. |

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (3) | Consists of options granted to Dr. Smith by the Compensation Committee on September 27, 2007, which vested as to 15,000 options on the date of grant and as to 10,000 options upon consummation of the our acquisition, on October 30, 2009, of China Biopharmaceuticals Holdings, Inc. (“CBH”) (such acquisition, the “Erye Merger”), which gave Caladrius a controlling 51% interest in Suzhou Erye Pharmaceutical Co. Ltd., CBH’s then primary operating subsidiary (“Erye”). |

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | Consists of options granted to Dr. Smith by the Compensation Committee on February 27, 2008, which vested (i) as to 4,000 options on the date of grant, (ii) as to 3,000 options upon consummation of the Erye Merger on October 30, 2009, (iii) as to 3,000 options on September 2, 2008 upon the achievement of a business milestone, and (iv) as to 2,000 options on October 31, 2008 upon the achievement of a business milestone. |

|     |                                                                                                                                                                     |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (5) | This option was granted to Dr. Smith by the Compensation Committee on October 31, 2008 and vested on November 2, 2008 upon the achievement of a business milestone. |

|     |                                                                                                                                        |
|-----|----------------------------------------------------------------------------------------------------------------------------------------|
| (6) | This option was granted to Dr. Smith by the Compensation Committee on May 8, 2009 and was vested in its entirety on the date of grant. |

|     |                                                                                                                                                                                                                                          |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (7) | This option was granted to Dr. Smith by the Compensation Committee on July 8, 2009 and vested as to 25,000 options on the date of grant and as to an additional 25,000 options upon consummation of the Erye Merger on October 30, 2009. |

|     |                                                                                                                                                                                                                                                                                                                                                                          |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (8) | An option was granted to Dr. Smith by the Compensation Committee effective October 29, 2009 upon approval of the Erye Merger and the increase in shares under the 2009 Plan consisting of an aggregate of 75,000 option shares, and was scheduled to vest as to 25,000 options upon the achievement of a specific business milestone, 25,000 options on July 8, 2010 and |

----

|     |                                                                                                                                             |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------|
| (9) | This option was granted to Dr. Smith by the Compensation Committee on October 30, 2009 and was vested in its entirety on the date of grant. |

|      |                                                                                                                                                                                                                                                                                                                                                                               |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (10) | This option was granted to Dr. Smith by the Compensation Committee on November 4, 2009 and originally scheduled to vest as to one-third of option shares on each one year anniversary of the date of grant. Pursuant to Dr. Smith's April 4, 2011 Employment Agreement amendment, the vesting of this option was accelerated and as of that date the option was fully vested. |

|      |                                                                                                                                                                                                                                                                                                                                                                                                   |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (11) | Consists of options granted to Dr. Smith pursuant to the terms of her April 4, 2011 Employment Agreement Amendment which vested as to 50,000 options on each of the date of grant and December 31, 2011 and was scheduled to vest as to 50,000 options on December 31, 2012. The vesting of this option was accelerated pursuant to Dr. Smith's November 13, 2012 Employment Agreement Amendment. |

|      |                                                                                                                                                                                                                                                                                                                                                                                            |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (12) | Consists of options granted to Dr. Smith by the Compensation Committee on January 4, 2012 which vested as to 26,333 options on the date of grant, and was scheduled to vest  as to (i) 26,333 options on January 4, 2013, and (ii) 26,334 options on January 4, 2014. The vesting of this option was accelerated pursuant to Dr. Smith's November 13, 2012 Employment Agreement Amendment. |

|      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (13) | On April 26, 2012, the Compensation Committee adopted the "2012 Option Program" whereby each participating officer was issued the "Option" to purchase that number of shares of our common stock equal to that portion of each Participating Officer's gross salary (the "Participating Salary") for the period "Election Period". The Option, the issuance of which is in lieu of payment of the Participating Salary vests at the end of the month in which the Participating Salary to which it relates would have been paid and has a term of ten years despite any termination of employment of the Participating Officer. Dr. Smith's Participating Salary for the Election Period was her full salary. Accordingly, the options vested as to 13,421 on May 31, 2012, 13,421 on June 30, 2012 and 13,421 on July 31, 2012. |

|      |                                                                                                                                         |
|------|-----------------------------------------------------------------------------------------------------------------------------------------|
| (14) | This option was granted to Dr. Smith by the Compensation Committee on July 5, 2012 and was vested in its entirety on the date of grant. |

|      |                                                                                                                                                                                                                                                                                                                                 |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (15) | Consists of options granted to Dr. Smith by the Compensation Committee on January 2, 2013 which vested as to 10,000 options on the date of grant, and as to 30,000 options in tranches of 10,000 options upon the achievement of specified milestones; 10,000 options shall vest upon the achievement of a specified milestone. |

|      |                                                                                                                                                                                                                                                                                                                                 |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (16) | Consists of options granted to Dr. Smith by the Compensation Committee on January 2, 2014 which vested as to 21,833 options on the date of grant, and as to 65,501 options in tranches of 21,834 options upon the achievement of specified milestones; 43,666 options shall vest upon the achievement of a specified milestone. |

|      |                                                                                                               |
|------|---------------------------------------------------------------------------------------------------------------|
| (17) | Consists of options granted to Dr. Smith effective on August 1, 2014 upon the closing of the CSC Acquisition. |

|      |                                                                                                                                                                                                                                                                                   |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (18) | Consists of options granted to Dr. Smith pursuant to the terms of her employment agreement amendment dated as of January 16, 2015, which are scheduled to vest as to one-third of the options on the date of grant, one-third on June 7, 2015, and one-third on December 7, 2015. |

|      |                                                                                                                                                                                                                                                                                         |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (19) | Consists of options granted to Dr. Smith by the Compensation Committee on January 2, 2015 which vested as to one-fourth of the options on the date of grant, and the remaining three-fourths of the options in three equal tranches upon the achievement of three specified milestones. |

|      |                                                                                                                                                                                                                                                                                                                                                                                                         |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (20) | Consists of options granted to Dr. Mazzo pursuant to the terms of his employment agreement dated as of January 5, 2015 and amended on January 16, 2015, which are scheduled to vest as to 100,000 options immediately, with the balance vesting in a series of sixteen successive equal quarterly installments (18,750 each) such that vesting is complete on the fourth anniversary of the grant date. |

|      |                                                                                                                                                                                                                                                                                                                                                                                                         |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (21) | Consists of options granted to Mr. Vaters pursuant to the terms of his employment agreement dated as of January 5, 2015 and amended on January 16, 2015, which are scheduled to vest as to 80,000 options immediately, with the balance vesting in a series of sixteen successive equal quarterly installments (20,000 each) such that vesting is complete on the fourth anniversary of the grant date. |

|      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (22) | Consists of options granted to Dr. Preti pursuant to the terms of his employment agreement dated as of September 23, 2010 and effective on January 19, 2011 upon the closing of the PCT Merger, which are scheduled to vest as to 10,000 options on each of the first and second annual anniversaries of the effective date and is scheduled to vest as to 10,000 options on each of the third and fourth annual anniversaries of the effective date of his employment agreement. |

----

|      |                                                                                                                                                                                                                                          |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (23) | Consists of options granted to Dr. Preti by the Compensation Committee on  January 4, 2012, which vested as to: (i) 9,213 options on January 4, 2012, (ii) 9,213 options on January 4, 2013 and, (iii) 9,214 options on January 4, 2014. |

|      |                                                                                                                                                                   |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (24) | Consists of options granted to Dr. Preti pursuant to the 2012 Option Program which vested as to 2,750 options on May 31, 2012 and 2,750 options on June 30, 2012. |

|      |                                                                                                                                                                                                                                                      |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (25) | Consists of options granted to Dr. Preti by the Compensation Committee on January 2, 2013 which vested as to 6,000 options on the date of grant, and as to 24,000 options in tranches of 6,000 options upon the achievement of specified milestones. |

|      |                                                                                                                                                                                                                                                                                                                                 |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (26) | Consists of options granted to Dr. Preti by the Compensation Committee on January 2, 2014 which vested as to 12,500 options on the date of grant, and as to 37,500 options in tranches of 12,500 options upon the achievement of specified milestones; 25,000 options shall vest upon the achievement of a specified milestone. |

|      |                                                                                                               |
|------|---------------------------------------------------------------------------------------------------------------|
| (27) | Consists of options granted to Dr. Preti effective on August 1, 2014 upon the closing of the CSC Acquisition. |

|      |                                                                                                                                           |
|------|-------------------------------------------------------------------------------------------------------------------------------------------|
| (28) | Consists of options granted to Dr. Preti effective on October 27, 2014 upon the  effective date of amendment to his employment agreement. |

|      |                                                                                                                                                                                                                                                                                         |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (29) | Consists of options granted to Dr. Preti by the Compensation Committee on January 2, 2015 which vested as to one-fourth of the options on the date of grant, and the remaining three-fourths of the options in three equal tranches upon the achievement of three specified milestones. |

|      |                                                                                                                                                                                                                                                                                                                                                                                                                       |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (30) | Consists of options granted to Dr. Preti effective June 2, 2015, based on the special efforts associated with the CIRM grant and capital raise, and for employee retention, which are scheduled to vest as to one-fourth of the options immediately, with the balance vesting in a series of twelve successive equal quarterly installments such that vesting is complete on the third anniversary of the grant date. |

|      |                                                                                                                                                                                                                                                                                                                                                                           |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (31) | Consists of options granted to Dr. Preti pursuant to the terms of his employment agreement amendment dated as of December 22, 2015, which are scheduled to vest as to 50,000 of the options immediately, with the balance vesting in a series of twelve successive equal quarterly installments such that vesting is complete on the third anniversary of the grant date. |

|      |                                                                                                                                                                                                                                         |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (32) | Consists of options granted to Dr. Losordo while he was a consultant for the Company on August 19, 2007, which vested as to 200 options on October 16, 2007, 200 options on October 16, 2008 and as to 200 options on October 16, 2009. |

|      |                                                                                                                                                                                                                                                                                                                                                                                                                     |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (33) | Consists of options granted to Dr. Losordo pursuant to the terms of his employment agreement dated as of July 23, 2013 and effective on August 5, 2013, which are scheduled to vest as to 20,000 options on each of the first and second annual anniversaries of the effective date of his employment agreement and as to 30,000 options on the third annual anniversaries of the effective date of his employment. |

|      |                                                                                                                                                                                                                                                                                                                                 |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (34) | Consists of options granted to Dr. Losordo by the Compensation Committee on January 2, 2014 which vested as to 8,333 options on the date of grant, and as to 25,001 options in tranches of 8,334 options upon the achievement of specified milestones; 16,666 options shall vest upon the achievement of a specified milestone. |

|      |                                                                                                                 |
|------|-----------------------------------------------------------------------------------------------------------------|
| (35) | Consists of options granted to Dr. Losordo effective on August 1, 2014 upon the closing of the CSC Acquisition. |

|      |                                                                                                                                                                                                                                                                                           |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (36) | Consists of options granted to Dr. Losordo by the Compensation Committee on January 2, 2015 which vested as to one-fourth of the options on the date of grant, and the remaining three-fourths of the options in three equal tranches upon the achievement of three specified milestones. |

|      |                                                                                                                                                                                                                                                                                                                                                                                                                         |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (37) | Consists of options granted to Dr. Losordo effective June 2, 2015, based on the special efforts associated with the CIRM grant and capital raise, and for employee retention, which are scheduled to vest as to one-fourth of the options immediately, with the balance vesting in a series of twelve successive equal quarterly installments such that vesting is complete on the third anniversary of the grant date. |

|      |                                                                                                                                                                                                                                                                                                                                     |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (38) | Consists of options granted to Mr. Talamo upon commencement of his employment on June 29, 2011, which are scheduled to vest as to 2,500 options on date of grant, as to 5,000 options on December 29, 2011, as to 5,000 options on June 29, 2012, as to 10,000 options on June 29, 2013, and as to 10,000 options on June 29, 2014. |

|      |                                                                                                                                                                                                                                           |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (39) | Consists of options granted to Mr. Talamo by the Compensation Committee on  January 4, 2012, which vested as to: (i) 2,500 options on January 4, 2012, (ii) 2,500 options on January 4, 2013 and, (iii) 2,500 options on January 4, 2014. |

|      |                                                                                                                                                                                                                                                       |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (40) | Consists of options granted to Mr. Talamo by the Compensation Committee on January 2, 2013 which vested as to 4,500 options on the date of grant, and as to 18,000 options in tranches of 4,500 options upon the achievement of specified milestones. |

|      |                                                                                                                                                                                                                                                                             |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (41) | Consists of options granted to Mr. Talamo by the Compensation Committee on January 2, 2014 which vested as to 8,750 options each on the date of grant and one year anniversary of the date of grant, and as to 17,500 options upon the achievement of specified milestones. |

----

|      |                                                                                                                |
|------|----------------------------------------------------------------------------------------------------------------|
| (42) | Consists of options granted to Mr. Talamo effective on August 1, 2014 upon the closing of the CSC Acquisition. |

|      |                                                                                                                                                                                                                                                                                          |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (43) | Consists of options granted to Mr. Talamo by the Compensation Committee on January 2, 2015 which vested as to one-fourth of the options on the date of grant, and the remaining three-fourths of the options in three equal tranches upon the achievement of three specified milestones. |

|      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (44) | Consists of options granted to Dr. Pecora pursuant to the terms of his employment agreement dated as of September 23, 2010 and effective on January 19, 2011 upon the closing of the PCT Merger, which are scheduled to vest as to 10,000 options on each of the first and second annual anniversaries of the effective date and is scheduled to vest as to 10,000 options on each of the third and fourth annual anniversaries of the effective date of his employment agreement. |

|      |                                                                                                                                                                                                                                                                                                                      |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (45) | Consists of options granted to Dr. Pecora pursuant to the terms of his August 17, 2011 Employment Agreement Amendment which vested as to 10,000 options on each of the effective date, August 17, 2012, August 17, 2013, and August 17, 2014 and which is scheduled to vest as to 10,000 options on August 17, 2015. |

|      |                                                                                                                                                                                                                          |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (46) | Consists of options granted to Dr. Pecora by the Compensation Committee on January 4, 2012 which vested as to 5,834 options on the date of grant, 5,833 options on January 4, 2013 and 5,844 options on January 4, 2014. |

|      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (47) | On April 26, 2012, the Compensation Committee adopted the 2012 Option Program. The Option, the issuance of which is in lieu of payment of the Participating Salary vests at the end of the month in which the Participating Salary to which it relates would have been paid and has a term of ten years despite any termination of employment of the Participating Officer. Dr. Pecora's Participating Salary for the Election Period was his full salary. Accordingly the options vested as to 4,666 on May 31, 2012, 4,667 on June 30, 2012 and 4,667 on July 31, 2012. |

|      |                                                                                                                                                                                                                                                                                                                               |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (48) | Consists of options granted to Dr. Pecora by the Compensation Committee on January 2, 2013 which vested as to 6,000 options on the date of grant, and as to 24,000 options in tranches of 6,000 options upon the achievement of specified milestones; 6,000 options shall vest upon the achievement of a specified milestone. |

|      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (49) | Consists of options granted to Dr. Pecora pursuant to the terms of his July 31, 2013 (effective August 5, 2013) Employment Agreement Amendment which vested as to 5,000 options on August 5, 2013, 12,500 options of September 30, 2013, 5,000 option shares on December 31, 2013, 3,125 options vested on December 16, 2013, and is scheduled to vest as to 5,000 option shares on December 31, 2014 and 9,375 options are scheduled to vest in tranches of 3,125 options upon achievement of three specified milestones. |

|      |                                                                                                                                                                                                                                                                                                                                  |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (50) | Consists of options granted to Dr. Pecora by the Compensation Committee on January 2, 2014 which vested as to 16,666 options on the date of grant, and as to 50,000 options in tranches of 16,667 options upon the achievement of specified milestones; 33,334 options shall vest upon the achievement of a specified milestone. |

|      |                                                                                                                                                                                                                                                                                          |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (51) | Consists of options granted to Dr. Pecora by the Compensation Committee on January 2, 2015 which vested as to one-fourth of the options on the date of grant, and the remaining three-fourths of the options in three equal tranches upon the achievement of three specified milestones. |

----

|                                                      |
|------------------------------------------------------|
|                                                      |  |  |  |  |  |  |  |  |
|                                                 |   |  Option Award |   | Stock Award |
| Name                                                 |   |  Number of Shares Acquired on Exercise |   |  Value Realized on Exercise |   | Number of Shares Acquired on Vesting |   | Value Realized on Vesting |
|                                                 |   | (#) |   | ($) |   | (#) |   | ($) |
| Dave J. Mazzo                                        |   | — |   | — |   | 189,543 |   | 623,010 |
| Chief Executive Officer (1)                          |   |   |   |   |   |   |   |   |
| Robin Smith                                          |   | — |   | — |   | 137,493 |   | 765,429 |
| Former Chief Executive Officer (2)                   |   |   |   |   |   |   |   |   |
| Joseph Talamo                                        |   | — |   | — |   | 8,438 |   | 19,069 |
| Chief Financial Officer (3)                          |   |   |   |   |   |   |   |   |
| Robert S. Vaters                                     |   | — |   | — |   | 135,365 |   | 397,870 |
| Former President and Chief Financial Officer (4)     |   |   |   |   |   |   |   |   |
| Robert Dickey, IV                                    |   | — |   | — |   | — |   | — |
|    Former Chief Financial Officer (5) |   |   |   |   |   |   |   |   |
| Robert Preti                                         |   | — |   | — |   | — |   | — |
| President and Chief Scientific Officer of PCT        |   |   |   |   |   |   |   |   |
| Douglas Losordo                                      |   | — |   | — |   | 10,000 |   | 15,900 |
| Chief Medical Officer                                |   |   |   |   |   |   |   |   |
| Andrew Pecora                                        |   | — |   | — |   | 14,517 |   | 44,688 |
| Former Chief Visionary Officer                       |   |   |   |   |   |   |   |   |

|     |                                                                                                             |
|-----|-------------------------------------------------------------------------------------------------------------|
| (1) | Effective January 5, 2015, Dr. Mazzo was appointed to serve as Chief Executive Officer of the Company. |

|     |                                                                                                                                                                                                                                                                                                                                                             |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Effective January 5, 2015, Dr. Smith resigned from her position as CEO and was appointed Executive Chair of the Board. Effective June 5, 2015, Dr. Smith resigned from her position as Executive Chair of the Board while continuing to serve as chair person of the Board.  Effective December 18, 2015, Dr. Smith resigned from the Board. |

|     |                                                                                                                   |
|-----|-------------------------------------------------------------------------------------------------------------------|
| (3) |  Effective October 5, 2015, Mr. Talamo was appointed to serve as Chief Financial Officer of the Company. |

|     |                                                                                                                                                                                                                                                                                     |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | Effective January 5, 2015, Mr. Vaters was appointed to serve as President and Chief Financial Officer of the Company.  Effective October 5, 2015, Mr. Vaters was no longer serving as President and Chief Financial Officer and was no longer an employee of the Company. |

|     |                                                                                                                                      |
|-----|--------------------------------------------------------------------------------------------------------------------------------------|
| (5) | Effective January 5, 2015, Mr. Dickey was no longer serving as Chief Financial Officer and was no longer an employee of the Company. |

----

|                       |
|-----------------------|
|                       |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                  |   | Fees Earned |   |   |   |   |   |   |
|                  |   | or |   | Stock |   | Option |   | Total |
| Name                  |   | Paid in Cash |   | Awards(1) |   | Awards(1) |   | Compensation |
| Richard Berman (2)    |   | $ | 40,000 |  |   | $ | 129,036 |  |   | $ | — |  |   | $169,036 |
| Steven S. Myers (3)   |   | $ | 40,000 |  |   | $ | 261,470 |  |   | $ | — |  |   | $301,470 |
| Drew Bernstein (4)    |   | $ | 21,522 |  |   | $ | 129,036 |  |   | $ | 65,921 |  |   | $216,479 |
| Eric C. Wei (5)       |   | $ | 40,000 |  |   | $ | 67,360 |  |   | $ | — |  |   | $107,360 |
| Martyn Greenacre (6)  |   | $ | 21,522 |  |   | $ | 74,820 |  |   | $ | — |  |   | $96,342 |
| Steven Klosk (7) |   | $ | 40,000 |  |   | $ | 67,360 |  |   | $ | — |  |   | $107,360 |
| Peter Traber (8)      |   | $ | 37,667 |  |   | $ | 122,280 |  |   | $ | 77,588 |  |   | $237,535 |
| Andrew Pecora (9)     |   | $ | 13,333 |  |   | $ | — |  |   | $ | 181,095 |  |   | $194,428 |
|                  |   | $ | 254,044 |  |   | $ | 851,362 |  |   | $ | 324,604 |  |   | $1,430,010 |

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (1) | Amounts shown under “Stock Awards" and "Option Awards” represent the aggregate grant date fair value computed in accordance with FASB ASC Topic 718, in accordance with SEC rules. See Note 13 to the Notes to the Consolidated Financial Statements in the 2015 Form 10-K for a discussion of assumptions made in such valuations. All stock awards, option awards and other shares discussed in this table were issued under the Company's 2003 Equity Participation Plan or the 2009 Amended & Restated Equity Compensation Plan, with a per share price generally equal to the fair market value of a share of our common stock on the date of grant. |

|     |                                                                                                                                                                                                                               |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | At December 31, 2015, Mr. Berman had a total of 38,766 shares in stock awards outstanding, of which 33,766 were vested, and options to purchase 34,939 shares of our common stock, all of which were vested. |

|     |                                                                                                                                                                                                                                     |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (3) | At December 31, 2015, Mr. Myers had a total of 414,805 shares in stock awards outstanding, of which 334,805 were vested.  and had options to purchase 34,939 shares of our common stock, all of which were vested. |

|     |                                                                                                                                                                                                                                |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | At December 31, 2015, Mr. Bernstein had a total of 10,000 shares in stock awards outstanding, all of which were vested, and had options to purchase 141,369 shares of our common stock, all of which were vested. |

|     |                                                                                                                                                                                                                               |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (5) | At December 31, 2015, Mr. Wei had a total of 10,000 shares in stock awards outstanding, of which 5,000 were vested, and had options to purchase 15,000 shares of our common stock, all of which were vested. |

|     |                                                                                                                                                                                                                          |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (6) | At December 31, 2015, Mr. Greenacre had a total of 88,531 shares in stock awards outstanding, all of which were vested.   warrants to purchase 25,000 shares of our common stock, all of which were vested. |

|     |                                                                                                                                                                                                                                    |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (7) | At December 31, 2015, Mr. Klosk had a total of 32,000 shares in stock awards outstanding, of which 27,000 were vested, and   had options to purchase 18,700 shares of our common stock, all of which were vested. |

|     |                                                                                                                                                                                                                                  |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (8) | At December 31, 2015, Mr. Traber had a total of 10,000 shares in stock awards outstanding, of which 5,000 were vested, and had options to purchase 28,000 shares of our common stock, all of which were vested. |

|     |                                                                                                                                                                                                                                                                                                                                        |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (9) | At December 31, 2015, Dr. Pecora had a total of 372,909 shares in stock awards outstanding, of which 356,626 were vested, had options to purchase 354,000 shares of our common stock, of which 337,333 were vested, and had warrants to purchase 35,860 shares of our common stock, all of which were vested. |

----

----

|         |                                       |
|---------|---------------------------------------|
| • | each of our named executive officers; |

|         |                                |
|---------|--------------------------------|
| • | each of our current directors; |

|         |                                                                     |
|---------|---------------------------------------------------------------------|
| • | all of our current directors and executive officers as a group; and |

|         |                                                                                         |
|---------|-----------------------------------------------------------------------------------------|
| • | each person who is known by us to beneficially own 5% or more of our Common Stock. |

|                                                                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                      |  |  |  |  |
| Name and Address of Beneficial Holder                                                                                                                                                       | Number of Shares Beneficially Owned |    | Percentage of Common Stock Beneficially Owned |
| David J. Mazzo                                                                                                                                                                  Chief Executive Officer and Director | 766,509 |  | (1)  | 1.3% |
| Robin L. Smith, M.D. Former Executive Chairman of the Board                                                                                                                                                     | 1,907,490 |  | (2)  | 3.2% |
| Joseph Talamo Chief Financial Officer                                                                                                                                                                           | 294,927 |  | (3)  | * |
| Robert S. Vaters Former President, Chief Financial Officer and Director                                                                                                                                              | 228,750 |  |   | * |
| Robert Dickey IV Former Chief Financial Officer                                                                                                                                                                 | 12,066 |  |   | * |
| Robert A. Preti, Ph.D. President and Chief Scientific Officer of PCT                                                                                                                                            | 699,337 |  | (4)  | 1.2% |
| Douglas Losordo, M.D. Chief Medical Officer                                                                                                                                                                     | 330,038 |  | (5)  | * |
| Andrew L. Pecora, M.D. Director                                                                                                                                                                                 | 755,102 |  | (6)  | 1.3% |
| Richard Berman Director                                                                                                                                                                                         | 82,705 |  | (7)  | * |
| Steven S. Myers Director                                                                                                                                                                                        | 458,744 |  | (8)  | * |
| Eric H.C. Wei Director                                                                                                                                                                                          | 2,556,988 |  | (9)  | 4.3% |
| Steven Klosk Director                                                                                                                                                                                           | 59,700 |  | (10)  | * |
| Peter G. Traber Director                                                                                                                                                                                        | 47,000 |  | (11)  | * |
| All Directors and Executive Officers as a group (ten persons)                                                                                                                                                        | 8,199,356 |  | (12)  | 13.1% |
| IEA Private Investments Ltd.                                                                                                                                                                                         | 4,172,435 |  | (13)  | 7.1% |

----

|     |                                                                                                                                         |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------|
| (1) | Includes  options to purchase up to 303,125 shares of our common stock which are exercisable within 60 days of April 22, 2016. |

|     |                                                                                                                                          |
|-----|------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Includes options to purchase up to 1,367,731 shares of our common stock which are exercisable within 60 days of April 22, 2016. |

|     |                                                                                                                                        |
|-----|----------------------------------------------------------------------------------------------------------------------------------------|
| (3) | Includes options to purchase up to 191,562 shares of our common stock which are exercisable within 60 days of April 22, 2016. |

|     |                                                                                                                                                                                                                                                                                    |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | Includes (i) options to purchase up to 379,155 shares of our common stock which are exercisable within 60 days of April 22, 2016, and  (ii) warrants to purchase up to 34,305 shares of our common stock which are exercisable within 60 days of April 22, 2016. |

|     |                                                                                                                                        |
|-----|----------------------------------------------------------------------------------------------------------------------------------------|
| (5) | Includes options to purchase up to 203,203 shares of our common stock which are exercisable within 60 days of April 22, 2016. |

|     |                                                                                                                                                                                                                                                                                    |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (6) | Includes (i) options to purchase up to 337,333 shares of our common stock which are exercisable within 60 days of April 22, 2016, and  (ii) warrants to purchase up to 35,860 shares of our common stock which are exercisable within 60 days of April 22, 2016. |

|     |                                                                                                                                       |
|-----|---------------------------------------------------------------------------------------------------------------------------------------|
| (7) | Includes options to purchase up to 34,939 shares of our common stock which are exercisable within 60 days of April 22, 2016. |

|     |                                                                                                                                       |
|-----|---------------------------------------------------------------------------------------------------------------------------------------|
| (8) | Includes options to purchase up to 34,939 shares of our common stock which are exercisable within 60 days of April 22, 2016. |

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (9) | Includes (i) options to purchase up to 15,000 shares of common stock which are exercisable within 60 days of April 22, 2016;  (ii) warrants to purchase up to 400,000 which are exercisable within 60 days of April 22, 2016 which are held by RimAsia;  RimAsia Capital Partners GP, L.P. ("RimAsia GP") is the general partner of RimAsia; (iii) 19,000 shares by Mr. Wei, individually; (iv) 2,110,988 shares of common stock by RimAsia Capital Partners L.P., a Cayman Islands exempted limited partnership ("RimAsia LP"), and  (v) 12,000 shares of common stock by RimAsia Capital Partners Manager, Ltd., a Cayman Islands exempted company ("RimAsia Manager"); RimAsia Capital Partners GP, Ltd. ("RimAsia Ltd.") is the general partner of RimAsia GP. RimAsia Manager is the fund manager of RimAsia GP and the manager of RimAsia. Mr. Wei is the managing partner of RimAsia, and indirect partner of RimAsia  GP, a director of RimAsia Ltd. and a director of RimAsia Manager. |

|      |                                                                                                                                       |
|------|---------------------------------------------------------------------------------------------------------------------------------------|
| (10) | Includes options to purchase up to 18,700 shares of our common stock which are exercisable within 60 days of April 22, 2016. |

|      |                                                                                                                                       |
|------|---------------------------------------------------------------------------------------------------------------------------------------|
| (11) | Includes options to purchase up to 28,000 shares of our common stock which are exercisable within 60 days of April 22, 2016. |

|      |                                                                                                                                          |
|------|------------------------------------------------------------------------------------------------------------------------------------------|
| (12) | Includes options to purchase up to 3,406,274 shares of our common stock which are exercisable within 60 days of March 31, 2016. |

|      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (13) | Based on information provided in a Schedule 13G filed by IEA Private Investments Ltd. on March 18, 2016, consists of 3,313,215 shares of common stock and warrants to purchase an additional 859,220 shares of common stock. The investment and voting decisions of IEA Private Investments Ltd. are made by its board of directors, consisting of Mark Siao Hing Pu and Amy Wu Yee, each of whom, in such capacity, may be deemed to beneficially own such shares. The business address of IEA Private Investments Ltd. is 3003A, ONE Exchange Square, 8 Connaught Place, Central, Hong Kong. |

----

|                                                            |
|------------------------------------------------------------|
|                                                            |  |  |  |  |
|                                                       | Equity Compensation Plan Information |
|                                                       | Number of securitiesto be issued upon exerciseof outstanding options (1) | Weighted Averageexercise price ofoutstanding optionsand rights | Number of securitiesremaining available forfuture issuance under equitycompensation plan(excluding securitiesreferenced in column (a)) |   |
| Equity compensation plans approved by security holders (2) | 6,663,270 | $6.46 | 5,459,206 | (3) |

|     |                                                                                                                                                                                                                                              |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (1) | Includes stock options only; does not include purchase rights accruing under the 2012 ESPP Plan because the purchase price (and therefore the number of shares to be purchased) will not be determined until the end of the purchase period. |

|     |                                                                                 |
|-----|---------------------------------------------------------------------------------|
| (2) | Consists of the 2003 Plan, the 2009 Plan, the 2012 ESPP Plan and the 2015 Plan. |

|     |                                                                                           |
|-----|-------------------------------------------------------------------------------------------|
| (3) | Includes shares available for future issuance under the 2009 Plan and the 2012 ESPP Plan. |

----

|         |                                                                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | whether the terms of the transaction are fair to the Company and on the same basis as would apply if the transaction did not involve a related party; |

|         |                                                                     |
|---------|---------------------------------------------------------------------|
| • | the business reasons for the Company to enter into the transaction; |

|         |                                                                                   |
|---------|-----------------------------------------------------------------------------------|
| • | whether the transaction would impair the independence of an independent director; |

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | whether the transaction would present an improper conflict of interest for any director or executive officer, taking into account the size of the transaction, the overall financial position of the director, executive officer or other related party, the direct or indirect nature of the director’s, executive officer’s or other related party’s interest in the transaction and the ongoing nature of any proposed relationship, and any other factors the Audit Committee deems relevant. |

----

|                       |
|-----------------------|
|                       |  |  |  |  |  |  |
| Fee Category     | Fiscal 2015 Fees | Fiscal 2014 Fees |
| Audit Fees(1)         | $ | 779,088 |  | $ | 594,844 |  |
| Audit-Related Fees(2) | $ | 262,500 |  | $ | — |  |
| Tax Fees(3)           | $ | — |  | $ | — |  |
| All Other Fees(4)     | $ | — |  | $ | 540,527 |  |
| Total Fees            | $ | 1,041,588 |  | $ | 1,135,371 |  |

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (1) | Audit Fees consist of aggregate fees billed or expected to be billed for professional services rendered for the audit of the Company's annual consolidated financial statements included in the Company's Annual Reports on Form 10-K and review of the interim consolidated financial statements included in Quarterly Reports on Form 10-Q or services that are normally provided by the independent registered public accounting firm in connection with statutory and regulatory filings or engagements for the fiscal years ended December 31, 2015 and 2014, respectively. |

|     |                                                                                                                                                                                                                                                                                                                                                                                  |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Audit-Related Fees consist of aggregate fees billed for assurance and related services that are reasonably related to the performance of the audit or review of the Company's consolidated financial statements and are not reported under “Audit Fees.”  The audit related services performed in 2015 were for services provided at the Company’s subsidiary. |

|     |                                                                                                                                                                                                                                                                                     |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (3) | Tax Fees consist of aggregate fees billed or expected to be billed for professional services rendered for tax compliance, tax advice and tax planning. These fees related to preparation of the Company's federal and state income tax returns and other tax compliance activities. |

|     |                                                                                                                                                                                                                                                      |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | All Other Fees consist of aggregate fees billed for products and services provided by Grant Thornton (as applicable), other than those disclosed above. The other fees related to due diligence services in connection with a potential transaction. |

----

|     |                                                                                                                                                                                                                                                                  |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.1 | Agreement and Plan of Merger dated as of May 8, 2014, by and among the Company, California Stem Cell, Inc., NBS Acquisition Sub I, Inc. and NBS Acquisition Sub II, LLC (filed as Exhibit 2.1 to the Company's Current Report on Form 8-K dated April 14, 2014). |

|     |                                                                                                                                                                                                                                                                                                                                    |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.2 | Equity Purchase Agreement, dated as of June 18, 2012, by and among the Company, China Biopharmaceuticals Holdings, Inc., Fullbright Finance Limited, Suzhou Erye Economy & Trading Co., Ltd., and Suzhou Erye Pharmaceutical Co., Ltd. (filed as Exhibit 2.1 to the Company's Current Report on Form 8-K dated June 18, 2012). |

|     |                                                                                                                                                                                                                                                                                                                                                                                  |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.3 | Amendment to Equity Purchase Agreement, dated as of August 14, 2012, by and among the Company, China Biopharmaceuticals Holdings, Inc., Highacheive Holdings Limited, Fullbright Finance Limited, Suzhou Erye Economy & Trading Co., Ltd. and Suzhou Erye Pharmaceutical Co., Ltd. (filed as Exhibit 2.1 to the Company's Current Report on Form 8-K dated August 23, 2012). |

|     |                                                                                                                                                                                                                                                                |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.4 | Agreement and Plan of Merger, dated as of July 13, 2011, by and among the Company, Amo Acquisition Company I, Inc., Amo Acquisition Company II, LLC and Amorcyte, Inc. (filed as Exhibit 2.1 to the Company's Current Report on Form 8-K dated July 11, 2011). |

|     |                                                                                                                                                                                                                           |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.5 | Agreement and Plan of Merger, dated as of September 23, 2010, by and among the Company, NBS Acquisition Company LLC, and PCT (filed as Exhibit 2.1 to the Company's Current Report on Form 8-K dated September 23, 2010). |

|     |                                                                                                                                                                                                                                                 |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1 | Amended and Restated Certificate of Incorporation of the Company, filed with the Secretary of State of the State of Delaware on October 3, 2013 (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K dated October 3, 2013). |

|     |                                                                                                                                           |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------|
| 3.2 | Amended and Restated By-Laws dated January 5, 2015 (filed as Exhibit 3.1 to the Company's Current Report on Form 8-K on January 5, 2015). |

|     |                                                                                                                                                                         |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.3 | Amendment to the By-Laws of the Company - Forum Selection Clause (filed as Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the SEC on June 5, 2015). |

|     |                                                                                                                                                                                                                                                                      |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.4 | Certificate of Amendment to Certificate of Incorporation of the Company dated May 29, 2015 (effective June 8, 2015) (filed as Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed with the SEC on August 6, 2015). |

|     |                                                                                                                                                                                           |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.1 | Form of Redeemable Service Provider Warrant (filed as Exhibit 4.19 to the Company's Registration Statement on Form S-3/A, File No. 333.173853, filed with the SEC on September 16, 2011). |

|     |                                                                                                                                                                                                |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.2 | Form of 2011 Redeemable Service Provider Warrant (filed as Exhibit 4.20 to the Company's Registration Statement on Form S-3/A, File No. 333-173853, filed with the SEC on September 16, 2011). |

|     |                                                                                                                                                                                                                         |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.3 | Form of Redeemable Service Provider Warrant with cashless exercise rights (filed as Exhibit 4.21 to the Company's Registration Statement on Form S-3/A, File No. 333-173853, filed with the SEC on September 16, 2011). |

----

|     |                                                                                                                                                                                                                                   |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.4 | Form of 2010/2011 Redeemable Service Provider Warrant with cashless exercise rights (filed as Exhibit 4.22 to the Company's Registration Statement on Form S-3/A, File No. 333-173853, filed with the SEC on September 16, 2011). |

|     |                                                                                                                                                                                                                                                         |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.5 | Letter Agreement dated December 18, 2008 between the Company and RimAsia Capital Partners, L.P. (filed as Exhibit 4.1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 as filed with the SEC on March 31, 2009). |

|     |                                                                                                                                                                                  |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.6 | Specimen Certificate for Common Stock (filed as Exhibit 4.1 to the Company's Registration Statement on Form S-3, File No. 333-145988, filed with the SEC on September 11, 2007). |

|     |                                                                                                                                                                                |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.7 | Form of Placement Agent Warrant from June 2010 (filed as Exhibit 4.2 to the Company's Current Report on Form 8-K dated June 25, 2010 and filed with the SEC on June 28, 2010). |

|     |                                                                                                                                                                                                                                |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.8 | Amended and Restated Warrant, dated March 15, 2010, issued to RimAsia Capital Partners, L.P. (filed as Exhibit 4.1 to the Company's Current Report on Form 8-K dated March 15, 2010 and filed with the SEC on March 18, 2010). |

|     |                                                                                                                                                                                    |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.9 | Form of Warrant from the November 2010 Common Stock Offering (filed as Exhibit 4.1 to the Company's Current Report on Form 8-K dated and filed with the SEC on November 16, 2010). |

|      |                                                                                                                                                                                                                                                                                                                                    |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.10 | Warrant Agreement, dated as of January 19, 2011, between the Company, and Continental Stock Transfer & Trust Company, with the forms of $3.00 Warrant and $5.00 Warrant attached thereto (filed as Exhibit 4.1 to the Company's Current Report on Form 8-K dated January 18, 2011 and filed with the SEC on January 24, 2011). |

|      |                                                                                                                                                                                                                                                                                                                                      |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.11 | Warrant Agreement, dated as of July 22, 2011, between the Company and Continental Stock Transfer & Trust Company, with the form of Series NA Warrant attached thereto (filed as Exhibit 4.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 as filed with the SEC on November 10, 2011). |

|      |                                                                                                                                                                                                                               |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.12 | Registration Rights Agreement, dated as of March 10, 2014, by and between the Company and Aspire Capital Fund, LLC. (Filed as Exhibit 4.18 to the Company's Annual Report on Form 10-K filed with the SEC on March 13, 2014). |

|      |                                                                                                                                                                                                                                                                                 |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.13 | Warrant Agreement, dated as of October 17, 2011, between the Company and Continental Stock Transfer & Trust Company, with the form of Global Series AMO Warrant attached thereto (filed as Exhibit 4.1 to the Company's Current Report on Form 8-K dated October 14, 2011). |

|      |                                                                                                                                                                          |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.14 | Form of Common Stock Purchase Warrant from the March 2012 Underwritten Offering (filed as Exhibit 4.1 to the Company's Current Report on Form 8-K dated March 29, 2012). |

|      |                                                                                                                                                                                                                                    |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.15 | Form of Common Stock Purchase Warrant for the May-July 2012 private placement (filed as Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 as filed with the SEC on August 14, 2012). |

|      |                                                                                                                                                                                         |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.16 | Form of New Warrant from July 2012 (filed as Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 as filed with the SEC on August 14, 2012). |

|      |                                                                                                                                                                                            |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.17 | Form of Warrant from August 2012 private placement (filed as Exhibit 4.6 to the Company's Registration Statement on Form S-3, File No. 333-183542, filed with the SEC on August 24, 2012). |

|      |                                                                                                                                                                                     |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.18 | Form of 2011/2012 Service Provider Warrant (filed as Exhibit 4.10 to the Company's Registration Statement on Form S-3, File No. 333-183542, filed with the SEC on August 24, 2012). |

|      |                                                                                                                                                                                                   |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.19 | Warrant issued to Aspire Capital Fund, LLC in August 2012 (filed as Exhibit 4.9 to the Company's Registration Statement on Form S-3, File No. 333-183542, filed with the SEC on August 24, 2012). |

|      |                                                                                                                                                                                                   |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.20 | Form of Warrant for November 2012 Unit private placement (filed as Exhibit 4.4 to the Company's Registration Statement on Form S-3, File No. 333-185346, filed with the SEC on December 7, 2012). |

|      |                                                                                                                                                                                                                                                                   |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.21 | Registration Rights Agreement, dated as of May 4, 2015, by and between the Company and Aspire Capital Fund, LLC (filed as Exhibit 4.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, as filed with the SEC on May 6, 2015). |

|      |                                                                                                                                                                 |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.22 | Form of Trust Indenture (filed as Exhibit 4.5 to the Company's Registration Statement on Form S-3, filed no. 333-206175, filed with the SEC on August 6, 2015). |

|      |                                                                                                                                                                 |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4.23 | Form of Trust Indenture (filed as Exhibit 4.5 to the Company's Registration Statement on Form S-3, filed no. 333-206175, filed with the SEC on August 6, 2015). |

|      |                                                                                                                                                                                                                                                          |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.1 | Consulting Agreement, dated as of May 11, 2010 between the Company and RimAsia Capital, Partners, LP (filed as Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 as filed with the SEC on August 6, 2010). |

----

|      |                                                                                                                                                                                                                    |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.2 | Common Stock Purchase Agreement, dated as of March 11, 2014, by and between the Company and Aspire Capital Fund, LLC. Filed as Exhibit 10.10 to the Company's Annual Report on Form 10-K filed on March 13, 2014). |

|      |                                                                                                                                                                                                                                                                                                 |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.3 | Escrow Agreement, dated as of October 17, 2011, among the Company, Amorcyte, Inc., Paul J. Schmitt, as Amorcyte Representative, and Continental Stock Transfer & Trust Company, as Escrow Agent (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated October 14, 2011). |

|      |                                                                                                                                                                                                                                                                                                      |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.4 | Lease dated September 1, 2005 between Vanni Business Park, LLC and PCT, as amended by First Amendment of Lease effective as of July 1, 2006 (filed as Exhibit 10.48 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010 as filed with the SEC on April 6, 2011). |

|      |                                                                                                                                                                                                                                                 |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.5 | Second Amendment of Lease, executed July 11, 2011 and effective July 1, 2011, by and between Vanni Business Park, LLC and Progenitor Cell Therapy, LLC (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated July 11, 2011). |

|      |                                                                                                                                                                                                                                 |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.6 | Guaranty of Lease, executed July 11, 2011 and effective as of July 1, 2011, by the Company for the benefit of Vanni Business Park, LLC (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K dated July 11, 2011). |

|      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.7 | First Amendment to Office Lease dated December 10, 2010, by and between WW VKO Owner, LLC and California Stem Cell, Inc; Second Amendment to Office Lease dated February 1, 2012, by and between CGGL 18301 LLC, and California Stem Cell, Inc. Third Amendment to Office Lease dated February 28, 2014, by and between CGGL 18301 LLC, and California Stem Cell, Inc.; and Fourth Amendment to Office Lease Agreement, executed December 19, 2014, effective April 1, 2015, by and between the Company and CGGL 18301 LLC. (filed as Exhibit 10.9 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 as filed with the SEC on March 2, 2015). |

|      |                                                                                                                                                                                                                                                                                         |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.8 | Stock Purchase and Assignment Agreement dated March 28, 2011, by and among PCT, Athelos Corporation and Becton Dickinson and Company (filed as Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 17, 2011). |

|      |                                                                                                                                                                                                                                                                         |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.9 | Stockholders' Agreement dated March 28, 2011, by and among PCT, Athelos Corporation and Becton Dickinson and Company (filed as Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 17, 2011). |

|       |                                                                                                                                                                                                     |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.10 | The Company 2003 Equity Participation Plan, as amended (filed as Exhibit 10.2 to the Company's Registration Statement on Form S-1/A, File No. 333-137045, filed with the SEC on November 3, 2006).+ |

|       |                                                                                                                                                                                          |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.11 | Form of Stock Option Agreement (filed as Exhibit 10.2 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2003 as filed with the SEC on March 30, 2004).+ |

|       |                                                                                                                                                                                                    |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.12 | Form of Option Agreement dated July 20, 2005 (filed as Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2005 as filed with the SEC on August 15, 2005).+ |

|       |                                                                                                                                                                                  |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.13 | Amended and Restated Company 2009 Equity Compensation Plan, as amended (filed as Annex A to the Company's Definitive Proxy Statement on Schedule 14A filed on August 29, 2014).+ |

|       |                                                                                                                                                                                                                                            |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.14 | Form of Stock Option Grant Agreement under the Company 2009 Equity Compensation Plan (filed as Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 as filed with the SEC on August 16, 2010).+ |

|       |                                                                                                                                                                                                                                                                                                                                                    |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.15 | Description of the Company's Board of Directors Compensation Plan (incorporated by reference to the first paragraph of Item 5.02 contained within the Company's Current Report on Form 8-K dated January 4, 2012, and the last paragraph appearing under Item 11 of this Annual Report on Form 10-K for the fiscal year ended December 31, 2012).+ |

|       |                                                                                                                                                                                                                            |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.16 | The Company's 2012 Employee Stock Purchase Plan (filed as Appendix A to the Company's Definitive Proxy Statement on Schedule 14A for the 2012 Annual Meeting of Stockholders as filed with the SEC on September 7, 2012).+ |

|       |                                                                                                                                                                                                         |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.17 | Loan and Security Agreement, dated September 26, 2014, by and between the Company and Oxford Finance LLC. (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated September 26, 2014). |

|       |                                                                                                                                                                              |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.18 | Employment Agreement between the Company and Dr. Robin L. Smith, dated May 26, 2006 (filed as Exhibit 10.4 to the Company's Current Report on Form 8-K dated June 2, 2006).+ |

|       |                                                                                                                                                                       |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.19 | January 26, 2007 Amendment to Employment Agreement of Dr. Robin L. Smith (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated January 26, 2007).+ |

|       |                                                                                                                                                                           |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.20 | September 27, 2007 Amendment to Employment Agreement of Dr. Robin L. Smith (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated September 27, 2007).+ |

|       |                                                                                                                                                            |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.21 | Letter agreement dated January 9, 2008 with Dr. Robin L. Smith (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated January 9, 2008).+ |

----

|       |                                                                                                                                                                                                               |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.22 | Amendment dated July 29, 2009 to Employment Agreement dated May 26, 2006 between the Company and Dr. Robin L. Smith (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated July 29, 2009).+ |

|       |                                                                                                                                                                                                                                                                               |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.23 | Amendment dated April 4, 2011 to Employment Agreement dated May 26, 2006 between the Company and Dr. Robin L. Smith (filed as Exhibit 10.66 to the Company's Annual Report on From 10-K for the fiscal year ended December 31, 2010 as filed with the SEC on April 6, 2011).+ |

|       |                                                                                                                                                                                                                                                                                   |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.24 | Amendment dated November 13, 2012 to Employment Agreement dated May 26, 2006 between the Company and Dr. Robin L. Smith (filed as Exhibit 10.43 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012 as filed with the SEC on March 8, 2013).+ |

|       |                                                                                                                                                                                                                                         |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.25 | Letter Agreement dated March 11, 2014 to Employment Agreement dated May 26, 2006 between the Company and Dr. Robin L. Smith (filed as Exhibit 10.49 to the Company's Annual Report on Form 10-K filed with the SEC on March 13, 2014).+ |

|       |                                                                                                                                                                                                                                                  |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.26 | Amendment dated as of January 1, 2015, to Employment Agreement by and between the Company and Dr. Robin L. Smith, dated May 26, 2006 (filed as Exhibit 10.1 on the Company's Current Report on Form 8-K filed with the SEC on January 5, 2015).+ |

|       |                                                                                                                                                                                                                                                                          |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.27 | Amendment, dated as of January 16, 2015, to Amendment dated as of January 1, 2015 to Employment Agreement by and between the Company and Dr. Robin L. Smith (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on January 16, 2015).+ |

|       |                                                                                                                                                                                                                     |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.28 | Consulting Agreement, dated as of December 18, 2015 by and between the Company and Dr. Robin L. Smith (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on December 23, 2015).+ |

|       |                                                                                                                                                                  |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.29 | January 26, 2007 Employment Agreement with Catherine M. Vaczy, Esq. (filed as Exhibit 10.4 to the Company's Current Report on Form 8-K dated January 26, 2007).+ |

|       |                                                                                                                                                                  |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.30 | Letter agreement dated January 9, 2008 with Catherine M. Vaczy, Esq. (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K dated January 9, 2008).+ |

|       |                                                                                                                                                                               |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.31 | Letter Agreement dated July 8, 2009 between the Company and Catherine M. Vaczy, Esq. (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K dated July 6, 2009).+ |

|       |                                                                                                                                                                                                                                                    |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.32 | Letter Agreement dated July 7, 2010 between the Company and Catherine M. Vaczy, Esq. (filed as Exhibit 10(a) to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 as filed with the SEC on November 12, 2010).+ |

|       |                                                                                                                                                                                                                                             |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.33 | Letter Agreement dated January 6, 2012 between the Company and Catherine M. Vaczy, Esq. (filed as Exhibit 10.92 to the Company's Annual Report on Form 10-K for the year ended December 31, 2011 as filed with the SEC on March 20, 2012).+ |

|       |                                                                                                                                                                                                                                                     |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.34 | Letter Agreement dated November 13, 2012 between the Company and Catherine M. Vaczy, Esq. (filed as Exhibit 10.57 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012 as filed with the SEC on March 8, 2013).+ |

|       |                                                                                                                                                                                         |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.35 | Letter Agreement, dated July 12, 2013, between the Company and Catherine M. Vaczy, Esq. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated July 12, 2013).+ |

|       |                                                                                                                                                                                                      |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.36 | Letter Agreement, dated March 11, 2014, between the Company and Catherine M. Vaczy, Esq. (filed as Exhibit 10.57 to the Company's Annual Report on Form 10-K filed with the SEC on March 13, 2014).+ |

|       |                                                                                                                                                                                                  |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.37 | Letter Agreement, dated August 4, 2014, between the Company and Catherine M. Vaczy, Esq. (filed as Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q with the SEC on August 7, 2014).+ |

|       |                                                                                                                                                                                                            |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.38 | Letter Agreement, dated October 27, 2014, between the Company and Catherine M. Vaczy, Esq. (filed as Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q filed with the SEC on October 30, 2014).+ |

|       |                                                                                                                                                                                                          |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.40 | Letter Agreement, dated February 5, 2015, between the Company and Catherine M. Vaczy, Esq. (filed as Exhibit 10.40 to the Company's Annual Report on Form 10-K/A filed with the SEC on April 30, 2015).+ |

|       |                                                                                                                                                                                                                                                                                                        |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.41 | Employment Agreement, dated as of September 23, 2010 and effective on January 19, 2011, by and between PCT, the Company, and Andrew L. Pecora, M.D., F.A.C.P.  (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated January 18, 2011 and filed with the SEC on January 24, 2011).+ |

----

|       |                                                                                                                                                                                                                                                                                                                              |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.42 | Amendment dated August 17, 2011 to Employment Agreement dated September 23, 2010 and effective January 19, 2011 between PCT, the Company, and Andrew L. Pecora, M.D., F.A.C.P.  (filed as Exhibit 10.95 to the Company's Registration Statement on Form S-4, File No. 333-176673, filed with the SEC on September 2, 2011).+ |

|       |                                                                                                                                                                                                                                                    |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.43 | Letter Agreement dated April 11, 2012 between the Company and Andrew Pecora, M.D., F.A.C.P. (filed as Exhibit 10.107 to the Company's Annual Report on Form 10-K/A for the year ended December 31, 2011 as filed with the SEC on April 27, 2012).+ |

|       |                                                                                                                                                                                                                                       |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.44 | Amendment dated July 31, 2013 and effective August 5, 2013, by and among Andrew L. Pecora, M.D., FACP, the Company, PCT, and Amorcyte, LLC (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K dated August 5, 2013).+ |

|       |                                                                                                                                                                                                                                                                                           |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.45 | Employment Agreement, dated as of September 23, 2010 and effective on January 19, 2011, by and between PCT, the Company, and Robert A. Preti, PhD (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K dated January 18, 2011 and filed with the SEC on January 24, 2011).+ |

|       |                                                                                                                                                                                                                                                                                                                                                                                        |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.46 | First Amendment to Employment Agreement, dated as of October 27, 2014, to Employment Agreement dated as of September 23, 2010 and effective on January 9, 2011, by and between PCT, the Company, and Robert A. Preti, PhD. (filed as Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 as filed with the SEC on October 30, 2014).+ |

|       |                                                                                                                                                                                                                                                                                                                                                                          |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.47 | Employment Agreement dated and effective as of December 22, 2015, to First Amendment to Employment dated as of October 27, 2014 to Employment Agreement dated as of September 23, 2010 and effective January 19, 2011, by and between the Company and Robert A. Preti, PhD (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K dated December 23, 2015).+ |

|       |                                                                                                                                                                                                                   |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.48 | Form of Indemnification Agreement for executive officers (filed as Exhibit 10.44 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 as filed with the SEC on March 2, 2015). |

|       |                                                                                                                                                                                                                                   |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.49 | Letter Agreement dated June 28, 2011 between the Company and Joseph Talamo (filed as Exhibit 10.10 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 as filed with the SEC on August 12, 2011).+ |

|       |                                                                                                                                                                                                   |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.51 | Employment Agreement, dated as of July 15, 2013, by and between the Company and Stephen W. Potter (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated July 15, 2013).+ |

|       |                                                                                                                                                                                                                                        |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.52 | Employment Agreement, dated as of July 23, 2013 and effective August 5, 2013, by and between the Company and Douglas W. Losordo, M.D. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated August 5, 2013).+ |

|       |                                                                                                                                                                                                                                    |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.53 | Employment Agreement, dated as of August 16, 2013 and effective August 19, 2013, by and between the Company and Robert Dickey IV (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated August 19, 2013).+ |

|       |                                                                                                                                                                                                              |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.54 | Offer Letter dated August 14, 2013 and effective August 19, 2013, by and between the Company and Larry May (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K dated August 19, 2013).+ |

|       |                                                                                                                                                                                                                                         |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.55 | Employment Agreement, dated as of January 5, 2015 and effective on January 5, 2015, by and between the Company and David J. Mazzo, Ph.D. (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K filed on January 5, 2015).+ |

|       |                                                                                                                                                                                                                                                                                      |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.56 | Amendment, dated as of January 16, 2015, to Employment Agreement, dated as of January 5, 2015 and effective on January 5, 2015, by and between the Company and David J. Mazzo, Ph.D. (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K filed on January 16, 2015).+ |

|       |                                                                                                                                                                                                                                     |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.57 | Employment Agreement, dated as of January 5, 2015 and effective on January 5, 2015, by and between the Company. and Robert S. Vaters (filed as Exhibit 10.3 to the Company's Current Report on Form 8-K filed on January 5, 2015).+ |

|       |                                                                                                                                                                                                                                                                                |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.58 | Amendment, dated as of January16, 2015, to Employment Agreement, dated as of January 5, 2015 and effective on January 5, 2015, by and between the Company and Robert S. Vaters (filed as Exhibit 10.3 to the Company's Current Report on Form 8-K filed on January 16, 2015).+ |

----

|       |                                                                                                                                                                                                                                                                            |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.60 | Common Stock Purchase Agreement, dated as of May 4, 2015, by and between the Company and Aspire Capital Fund, LLC (filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, as filed with the SEC on May 6, 2015). |

|       |                                                                                                                                                                                                                                                                                |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.61 | First Amendment to Loan and Security Agreement, dated June 17, 2015, by and between the Company and Oxford Finance LLC (filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed with the SEC on August 6, 2015). |

|       |                                                                                                                                                                           |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.62 | The Company 2015 Equity Compensation Plan (filed as Annex A to the Company’s Definitive Proxy Statement filed on Schedule 14A, filed with the SEC on June 8, 2015). |

|       |                                                                                                                                                                                                                                                                                             |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.63 | Second Amendment to Loan and Security Agreement, dated September 15, 2015, by and between the Company and Oxford Finance LLC (filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed with the SEC on November 5, 2015). |

|       |                                                                                                                                                                                                                                                                                       |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.64 | Common Stock Purchase Agreement, dated as of November 4, 2015, by and between the Company and Aspire Capital Fund, LLC (filed as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed with the SEC on November 5, 2015). |

|       |                                                                                                                                                                                                               |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.65 | Consulting Agreement, dated December 18, 2015, between the Company and Dr. Robin L. Smith (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 23, 2015).+ |

|       |                                                                                                                                                                                                                                      |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.66 | Employment Agreement, dated and effective as of December 22, 2015, among PCT, the Company, and Robert Preti, PhD (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on December 23, 2015).+ |

|      |                                                                                                                                                                                                      |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 14.1 | Code of Ethics for Senior Financial Officers (filed as Exhibit 14.1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010 as filed with the SEC on April 6, 2011). |

|      |                                                                                                                                                                                                     |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 21.1 | Subsidiaries of Caladrius Biosciences, Inc (filed as Exhibit 21.1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 as filed with the SEC on March 15, 2016). |

|      |                                                                                                                                                                                        |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 23.1 | Consent of Grant Thornton LLP (filed as Exhibit 23.1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 as filed with the SEC on March 15, 2016). |

|      |                                                                                                                                                                                                                                                             |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed as Exhibit 31.1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 as filed with the SEC on March 15, 2016). |

|      |                                                                                                                                                                                                                                                             |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed as Exhibit 31.2 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 as filed with the SEC on March 15, 2016). |

|             |                                                                                                     |
|-------------|-----------------------------------------------------------------------------------------------------|
| 31.3† | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |

|             |                                                                                                     |
|-------------|-----------------------------------------------------------------------------------------------------|
| 31.4† | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |

|      |                                                                                                                                                                                                                                                                                                            |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 32.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed as Exhibit 32.1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 as filed with the SEC on March 15, 2016). |

|      |                                                                                                                                                                                                                                                                                                            |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 32.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed as Exhibit 32.2 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 as filed with the SEC on March 15, 2016). |

|         |                        |
|---------|------------------------|
| 101.INS | XBRL Instance Document |

|         |                                |
|---------|--------------------------------|
| 101.SCH | XBRL Taxonomy Extension Schema |

|         |                                              |
|---------|----------------------------------------------|
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase |

|         |                                             |
|---------|---------------------------------------------|
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase |

|         |                                        |
|---------|----------------------------------------|
| 101.LAB | XBRL Taxonomy Extension Label Linkbase |

|         |                                                                       |
|---------|-----------------------------------------------------------------------|
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase     |

|   |                                                                                                                                                             |
|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| + | Management contract or compensatory plan, contract or arrangement required to be filed as an exhibit to this Form 10-K pursuant to Item 15(b) of Form 10-K. |

----

|              |
|--------------|
|              |  |  |
|         |   |   |
|         |   | CALADRIUS BIOSCIENCES, INC. |
|    |   | By:/s/ David J. Mazzo, PhDName: David J. Mazzo Title: Chief Executive Officer |